<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK1410" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK1410/" /><meta name="ncbi_pagename" content="X-Linked Severe Combined Immunodeficiency - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>X-Linked Severe Combined Immunodeficiency - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="X-Linked Severe Combined Immunodeficiency" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2016/04/14" /><meta name="citation_author" content="Eric Allenspach" /><meta name="citation_author" content="David J Rawlings" /><meta name="citation_author" content="Andrew M Scharenberg" /><meta name="citation_pmid" content="20301584" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK1410/" /><meta name="citation_keywords" content="SCIDX1" /><meta name="citation_keywords" content="X-Linked SCID" /><meta name="citation_keywords" content="X-SCID" /><meta name="citation_keywords" content="SCIDX1" /><meta name="citation_keywords" content="X-SCID" /><meta name="citation_keywords" content="Cytokine receptor common subunit gamma" /><meta name="citation_keywords" content="IL2RG" /><meta name="citation_keywords" content="X-Linked Severe Combined Immunodeficiency" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="X-Linked Severe Combined Immunodeficiency" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Eric Allenspach" /><meta name="DC.Contributor" content="David J Rawlings" /><meta name="DC.Contributor" content="Andrew M Scharenberg" /><meta name="DC.Date" content="2016/04/14" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK1410/" /><meta name="description" content="X-linked severe combined immunodeficiency (X-SCID) is a combined cellular and humoral immunodeficiency caused by a hemizygous pathogenic variant in IL2RG. In typical X-SCID lack of IL2RG function results in near-complete absence of T and natural killer (NK) lymphocytes and nonfunctional B lymphocytes. X-SCID is almost universally fatal in the first two years of life unless reconstitution of the immune system is achieved through bone marrow transplant or gene therapy. In the absence of family history of X-SCID and prior to newborn screening for X-SCID, most males with typical X-SCID come to medical attention between ages three and six months with failure to thrive, oral/diaper candidiasis, absent tonsils and lymph nodes, recurrent infections, infections with opportunistic organisms such as Pneumocystis, and persistence of infections despite conventional treatment. Additional common features include rashes, diarrhea, cough and congestion, fevers, pneumonia, sepsis, and other severe bacterial infections. Males with atypical X-SCID may have immune dysregulation and autoimmunity associated with rashes, gastrointestinal malabsorption, and short stature." /><meta name="og:title" content="X-Linked Severe Combined Immunodeficiency" /><meta name="og:type" content="book" /><meta name="og:description" content="X-linked severe combined immunodeficiency (X-SCID) is a combined cellular and humoral immunodeficiency caused by a hemizygous pathogenic variant in IL2RG. In typical X-SCID lack of IL2RG function results in near-complete absence of T and natural killer (NK) lymphocytes and nonfunctional B lymphocytes. X-SCID is almost universally fatal in the first two years of life unless reconstitution of the immune system is achieved through bone marrow transplant or gene therapy. In the absence of family history of X-SCID and prior to newborn screening for X-SCID, most males with typical X-SCID come to medical attention between ages three and six months with failure to thrive, oral/diaper candidiasis, absent tonsils and lymph nodes, recurrent infections, infections with opportunistic organisms such as Pneumocystis, and persistence of infections despite conventional treatment. Additional common features include rashes, diarrhea, cough and congestion, fevers, pneumonia, sepsis, and other severe bacterial infections. Males with atypical X-SCID may have immune dysregulation and autoimmunity associated with rashes, gastrointestinal malabsorption, and short stature." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK1410/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/x-scid/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK1410/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE88DFEDE040C1410000000000160004.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK1410_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK1410_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/epp-xl/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/sider-anemia/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK1410_"><span class="title" itemprop="name">X-Linked Severe Combined Immunodeficiency</span></h1><div itemprop="alternativeHeadline" class="subtitle whole_rhythm">Synonyms: SCIDX1, X-Linked SCID, X-SCID</div><p class="contrib-group"><span itemprop="author">Eric Allenspach</span>, MD, PhD, <span itemprop="author">David J Rawlings</span>, MD, and <span itemprop="author">Andrew M Scharenberg</span>, MD.</p><a data-jig="ncbitoggler" href="#__NBK1410_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK1410_ai__"><div class="contrib half_rhythm"><span itemprop="author">Eric Allenspach</span>, MD, PhD<div class="affiliation small">University of Washington<br />Seattle, Washington<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="gro.snerdlihcelttaes@hcapsnella.cire" class="oemail">gro.snerdlihcelttaes@hcapsnella.cire</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">David J Rawlings</span>, MD<div class="affiliation small">University of Washington<br />Seattle, Washington<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.notgnihsaw.u@gnilward" class="oemail">ude.notgnihsaw.u@gnilward</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Andrew M Scharenberg</span>, MD<div class="affiliation small">University of Washington<br />Seattle, Washington<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.notgnihsaw.u@smwerdna" class="oemail">ude.notgnihsaw.u@smwerdna</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">August 26, 2003</span>; Last Update: <span itemprop="dateModified">April 14, 2016</span>.</p><p><em>Estimated reading time: 25 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="x-scid.Summary" itemprop="description"><h2 id="_x-scid_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p><a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> severe combined immunodeficiency (X-SCID) is a combined cellular and humoral immunodeficiency caused by a <a class="def" href="/books/n/gene/glossary/def-item/hemizygous/">hemizygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>IL2RG</i>. In typical X-SCID lack of <i>IL2RG</i> function results in near-complete absence of T and natural killer (NK) lymphocytes and nonfunctional B lymphocytes. X-SCID is almost universally fatal in the first two years of life unless reconstitution of the immune system is achieved through bone marrow transplant or <a class="def" href="/books/n/gene/glossary/def-item/gene-therapy/">gene therapy</a>. In the absence of family history of X-SCID and prior to <a class="def" href="/books/n/gene/glossary/def-item/newborn-screening/">newborn screening</a> for X-SCID, most males with typical X-SCID come to medical attention between ages three and six months with failure to thrive, oral/diaper candidiasis, absent tonsils and lymph nodes, recurrent infections, infections with opportunistic organisms such as <i>Pneumocystis</i>, and persistence of infections despite conventional treatment. Additional common features include rashes, diarrhea, cough and congestion, fevers, pneumonia, sepsis, and other severe bacterial infections. Males with atypical X-SCID may have immune dysregulation and autoimmunity associated with rashes, gastrointestinal malabsorption, and short stature.</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>In many states, testing for X-SCID is now frequently part of <a class="def" href="/books/n/gene/glossary/def-item/newborn-screening/">newborn screening</a>. Follow-up confirmatory testing includes lymphocyte counts, lymphocyte subset enumeration by flow cytometry, and molecular testing of <i>IL2RG,</i> the only <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> in which pathogenic variants are known to cause X-SCID. Absolute lymphocyte count compared to age-matched normal infants is usually low. The number of T cells is usually very low; B cells are generally present but nonfunctional; NK cells are low or absent. Sequence analysis of the <i>IL2RG</i> <a class="def" href="/books/n/gene/glossary/def-item/coding-region/">coding region</a> detects a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in more than 99% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> males.</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i> Immune reconstitution by bone marrow transplantation (BMT) or <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> replacement therapy is required for survival; thus, diagnosis at as young an age as possible enables early immune reconstitution and prevents difficult-to-treat infections that may compromise vital organs. In the interval between diagnosis and immune reconstitution, management includes treatment of infections, immunoglobulin infusions and prophylactic antibiotics (particularly against <i>Pneumocystis jirovecii</i>), and isolation from cytomegalovirus (CMV) exposures.</p><p><i>Prevention of primary manifestations:</i> BMT using HLA-matched bone marrow from a relative is presently the preferred option. Haploidentical parental bone marrow depleted of mature T cells or matched, unrelated bone marrow or cord blood stem cells can be used for transplantation as well, but each has particular conditioning and graft-versus-host disease risks to consider along with infection status. The best timing for BMT is immediately after birth. Infants undergoing transplantation in the first 3.5 months of life have a much higher rate of survival than those undergoing transplantation later. Long-term periodic administration of immunoglobulin may be required in those who fail to develop allogeneic, functional B lymphocytes. Gene therapy using retroviral transduction of autologous bone marrow stem/progenitor cells with a therapeutic <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> has been successful for T-cell immune reconstitution for some individuals, but is presently only considered for those who are not candidates for BMT or have failed BMT.</p><p><i>Prevention of secondary complications:</i>
<i>Pneumocystis jirovecii</i>, viral and encapsulated organism prophylaxis should be applied per transplantation protocols; IVIG prophylaxis should be considered to maintain serum IgG levels above 400mg/dL; prompt evaluation of illness should occur until the individual is immunologically competent; avoid immunizations until after restoration of immunocompetence; only use CMV-negative, irradiated blood products; avoid breast feeding and exposure to young children to prevent CMV transmission to babies with X-SCID.</p><p><i>Surveillance:</i> Monitor growth, immune and lung function, and gastrointestinal and dermatologic findings every 6-12 months after successful BMT.</p><p><i>Agents/circumstances to avoid:</i> Live vaccines; transfusion of non-irradiated blood products; breast-feeding and breast milk; exposure to young children, sick contacts, or individuals with cold sores.</p><p><i>Evaluation of relatives at risk:</i> When the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in the family is known, <a class="def" href="/books/n/gene/glossary/def-item/prenatal-diagnosis/">prenatal diagnosis</a> of at-risk males allows preparation for bone marrow transplantation to be initiated before birth.</p><p><i>Therapies under investigation:</i> A variety of second-generation therapeutic <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> transfer vectors for X-SCID are presently under evaluation in clinical trials that have removed the likely cancer-causing elements from the vectors.</p></div><div><h4 class="inline">Genetic counseling.</h4><p>X-SCID is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> manner. More than half of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> males have no family history of early deaths in maternal male relatives. If the mother of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> is a <a class="def" href="/books/n/gene/glossary/def-item/heterozygote/">heterozygote</a> (<a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>), the chance of transmitting the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in each pregnancy is 50%. Males who inherit the pathogenic variant will be affected; females who inherit the pathogenic variant will be heterozygotes (carriers) and will not be affected. Males with X-SCID will pass the pathogenic variant to all of their daughters and none of their sons. Carrier testing of at-risk female relatives is most informative if the <i>IL2RG</i> pathogenic variant has been identified in an affected family member. Prenatal testing is possible for pregnancies at increased risk if the <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> pathogenic variant is known.</p></div></div><div id="x-scid.Diagnosis"><h2 id="_x-scid_Diagnosis_">Diagnosis</h2><div id="x-scid.Suggestive_Findings"><h3>Suggestive Findings</h3><p><a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> severe combined immunodeficiency (X-SCID) <b>should be suspected</b> in male infants with recurrent or persistent infections that are severe, unresponsive to ordinary treatment, caused by opportunistic pathogens, or associated with failure to thrive or chronic diarrhea. Asymptomatic children with abnormal <a class="def" href="/books/n/gene/glossary/def-item/newborn-screening/">newborn screening</a> or family history of X-SCID should be fully evaluated.</p><p><b>Supportive laboratory and radiographic findings</b></p><ul><li class="half_rhythm"><div>Low T-cell receptor excision circles (TRECs) on <a class="def" href="/books/n/gene/glossary/def-item/newborn-screening/">newborn screening</a></div></li><li class="half_rhythm"><div>Marked lymphocytopenia (&#x0003c;3400 cells/mm<sup>3</sup> for 0-3 months) and/or T-cell (CD3+) lymphopenia (&#x0003c;1500 cells/mm<sup>3</sup>)</div></li><li class="half_rhythm"><div>Severe defect in T-cell proliferation to the mitogen PHA (&#x0003c;10% of the lower limit of the reference/normal response)</div></li><li class="half_rhythm"><div>Marked decrease in thymic function: decreased or absent CD4+CD45RA+ na&#x000ef;ve T cells or TRECs</div></li><li class="half_rhythm"><div>Absent thymic shadow on chest radiogram</div></li><li class="half_rhythm"><div>Decreased IL-21-induced STAT3 phosphorylation on functional testing compared to healthy controls, which indicates defective common-gamma chain function in B cells</div></li><li class="half_rhythm"><div>Negative HIV viral load testing (RNA/DNA assay)</div></li></ul></div><div id="x-scid.Newborn_Screening"><h3>Newborn Screening</h3><p>In 2010 the US Department of Health and Human Services recommended adding severe combined immunodeficiency (SCID) to the nationally reviewed uniform panel of conditions subject to <a class="def" href="/books/n/gene/glossary/def-item/newborn-screening/">newborn screening</a>. Universal newborn screening for SCID is now available in most states: thirty-four states, the District of Columbia, and the Navajo Nation have implemented screening, and seven additional states (Alabama, Georgia, Louisiana, Maryland, North Carolina, Kentucky, and Tennessee) are expected to start screening in 2016.</p><ul><li class="half_rhythm"><div>Low TREC detection from DNA extracted from the Guthrie blood spot indicates possible lymphopenia [<a class="bk_pop" href="#x-scid.REF.chan.2005.391">Chan &#x00026; Puck 2005</a>, <a class="bk_pop" href="#x-scid.REF.baker.2009.522">Baker et al 2009</a>, <a class="bk_pop" href="#x-scid.REF.chase.2010.521">Chase et al 2010</a>].</div></li><li class="half_rhythm"><div>Newborn screening laboratories contact primary care physicians with positive (low) TREC results prompting further flow cytometric testing to assay for T-cell lymphopenia and confirmatory <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> as indicated.</div></li></ul><p><a href="http://primaryimmune.org/wp-content/uploads/2011/11/SCID_FLYER_11-11_revised.pdf" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Educational materials</a> from the Immune Deficiency Foundation <a href="http://primaryimmune.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">website</a> are available for families receiving an abnormal screen.</p><p><b>Lymphocyte count.</b> The absolute lymphocyte count compared to age-matched normal infants is usually low (see <a class="figpopup" href="/books/NBK1410/table/x-scid.T.lymphocyte_counts_in_infants_wi/?report=objectonly" target="object" rid-figpopup="figxscidTlymphocytecountsininfantswi" rid-ob="figobxscidTlymphocytecountsininfantswi">Table 1</a>) [<a class="bk_pop" href="#x-scid.REF.buckley.1997.378">Buckley et al 1997</a>, <a class="bk_pop" href="#x-scid.REF.myers.2002.872">Myers et al 2002</a>, <a class="bk_pop" href="#x-scid.REF.shearer.2003.973">Shearer et al 2003</a>].</p><ul><li class="half_rhythm"><div>The number of T cells is usually very low.</div></li><li class="half_rhythm"><div>B cells are generally present, but dysfunctional.</div></li><li class="half_rhythm"><div>NK cells are low in number or absent.</div></li></ul><p>Typical X-SCID is designated T<sup>&#x02013;</sup>B<sup>+</sup>NK<sup>&#x02013;</sup>.</p><div id="x-scid.T.lymphocyte_counts_in_infants_wi" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Lymphocyte Counts in Infants with X-Linked Severe Combined Immunodeficiency</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1410/table/x-scid.T.lymphocyte_counts_in_infants_wi/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__x-scid.T.lymphocyte_counts_in_infants_wi_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_x-scid.T.lymphocyte_counts_in_infants_wi_1_1_1_1" rowspan="2" scope="col" colspan="1" headers="hd_h_x-scid.T.lymphocyte_counts_in_infants_wi_1_1_1_1" style="text-align:left;vertical-align:middle;">Cell Type</th><th id="hd_h_x-scid.T.lymphocyte_counts_in_infants_wi_1_1_1_2" colspan="2" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Lymphocyte Counts</th><th id="hd_h_x-scid.T.lymphocyte_counts_in_infants_wi_1_1_1_3" rowspan="2" scope="col" colspan="1" headers="hd_h_x-scid.T.lymphocyte_counts_in_infants_wi_1_1_1_3" style="text-align:left;vertical-align:middle;">% of Affected Individuals</th><th id="hd_h_x-scid.T.lymphocyte_counts_in_infants_wi_1_1_1_4" colspan="2" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Control Values</th></tr><tr><th headers="hd_h_x-scid.T.lymphocyte_counts_in_infants_wi_1_1_1_2" id="hd_h_x-scid.T.lymphocyte_counts_in_infants_wi_1_1_2_1" colspan="1" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Average</th><th headers="hd_h_x-scid.T.lymphocyte_counts_in_infants_wi_1_1_1_2" id="hd_h_x-scid.T.lymphocyte_counts_in_infants_wi_1_1_2_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Range</th><th headers="hd_h_x-scid.T.lymphocyte_counts_in_infants_wi_1_1_1_4" id="hd_h_x-scid.T.lymphocyte_counts_in_infants_wi_1_1_2_3" colspan="1" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Average</th><th headers="hd_h_x-scid.T.lymphocyte_counts_in_infants_wi_1_1_1_4" id="hd_h_x-scid.T.lymphocyte_counts_in_infants_wi_1_1_2_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Range</th></tr></thead><tbody><tr><td headers="hd_h_x-scid.T.lymphocyte_counts_in_infants_wi_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;">Total lymphocytes</td><td headers="hd_h_x-scid.T.lymphocyte_counts_in_infants_wi_1_1_1_2 hd_h_x-scid.T.lymphocyte_counts_in_infants_wi_1_1_2_1" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003c;2,000</td><td headers="hd_h_x-scid.T.lymphocyte_counts_in_infants_wi_1_1_1_2 hd_h_x-scid.T.lymphocyte_counts_in_infants_wi_1_1_2_2" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_x-scid.T.lymphocyte_counts_in_infants_wi_1_1_1_3" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;">70%</td><td headers="hd_h_x-scid.T.lymphocyte_counts_in_infants_wi_1_1_1_4 hd_h_x-scid.T.lymphocyte_counts_in_infants_wi_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">5,400&#x000a0;<sup>1</sup></td><td headers="hd_h_x-scid.T.lymphocyte_counts_in_infants_wi_1_1_1_4 hd_h_x-scid.T.lymphocyte_counts_in_infants_wi_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">3,400-7,600&#x000a0;<sup>1</sup></td></tr><tr><td headers="hd_h_x-scid.T.lymphocyte_counts_in_infants_wi_1_1_1_4 hd_h_x-scid.T.lymphocyte_counts_in_infants_wi_1_1_2_3" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">5,500&#x000a0;<sup>2</sup></td><td headers="hd_h_x-scid.T.lymphocyte_counts_in_infants_wi_1_1_1_4 hd_h_x-scid.T.lymphocyte_counts_in_infants_wi_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003e;2,000&#x000a0;<sup>2</sup></td></tr><tr><td headers="hd_h_x-scid.T.lymphocyte_counts_in_infants_wi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">T cells</td><td headers="hd_h_x-scid.T.lymphocyte_counts_in_infants_wi_1_1_1_2 hd_h_x-scid.T.lymphocyte_counts_in_infants_wi_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">200</td><td headers="hd_h_x-scid.T.lymphocyte_counts_in_infants_wi_1_1_1_2 hd_h_x-scid.T.lymphocyte_counts_in_infants_wi_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0-800</td><td headers="hd_h_x-scid.T.lymphocyte_counts_in_infants_wi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">90%-95%&#x000a0;<sup>3</sup></td><td headers="hd_h_x-scid.T.lymphocyte_counts_in_infants_wi_1_1_1_4 hd_h_x-scid.T.lymphocyte_counts_in_infants_wi_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">3,680&#x000a0;<sup>1</sup></td><td headers="hd_h_x-scid.T.lymphocyte_counts_in_infants_wi_1_1_1_4 hd_h_x-scid.T.lymphocyte_counts_in_infants_wi_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">2,500-5,500&#x000a0;<sup>1</sup></td></tr><tr><td headers="hd_h_x-scid.T.lymphocyte_counts_in_infants_wi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">B cells</td><td headers="hd_h_x-scid.T.lymphocyte_counts_in_infants_wi_1_1_1_2 hd_h_x-scid.T.lymphocyte_counts_in_infants_wi_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1,300</td><td headers="hd_h_x-scid.T.lymphocyte_counts_in_infants_wi_1_1_1_2 hd_h_x-scid.T.lymphocyte_counts_in_infants_wi_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">44 - &#x0003e;3,000&#x000a0;<sup>4</sup></td><td headers="hd_h_x-scid.T.lymphocyte_counts_in_infants_wi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">95%</td><td headers="hd_h_x-scid.T.lymphocyte_counts_in_infants_wi_1_1_1_4 hd_h_x-scid.T.lymphocyte_counts_in_infants_wi_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">730&#x000a0;<sup>1</sup></td><td headers="hd_h_x-scid.T.lymphocyte_counts_in_infants_wi_1_1_1_4 hd_h_x-scid.T.lymphocyte_counts_in_infants_wi_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">300-2,000&#x000a0;<sup>1</sup></td></tr><tr><td headers="hd_h_x-scid.T.lymphocyte_counts_in_infants_wi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">NK cells</td><td headers="hd_h_x-scid.T.lymphocyte_counts_in_infants_wi_1_1_1_2 hd_h_x-scid.T.lymphocyte_counts_in_infants_wi_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003c;100</td><td headers="hd_h_x-scid.T.lymphocyte_counts_in_infants_wi_1_1_1_2 hd_h_x-scid.T.lymphocyte_counts_in_infants_wi_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_x-scid.T.lymphocyte_counts_in_infants_wi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">88%</td><td headers="hd_h_x-scid.T.lymphocyte_counts_in_infants_wi_1_1_1_4 hd_h_x-scid.T.lymphocyte_counts_in_infants_wi_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">420&#x000a0;<sup>1</sup></td><td headers="hd_h_x-scid.T.lymphocyte_counts_in_infants_wi_1_1_1_4 hd_h_x-scid.T.lymphocyte_counts_in_infants_wi_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">170-1,100&#x000a0;<sup>1</sup></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Adapted from <a class="bk_pop" href="#x-scid.REF.conley.1990.1548">Conley et al [1990]</a>, <a class="bk_pop" href="#x-scid.REF.stephan.1993.564">Stephan et al [1993]</a>, <a class="bk_pop" href="#x-scid.REF.buckley.1997.378">Buckley et al [1997]</a>, <a class="bk_pop" href="#x-scid.REF.buckley.1999.508">Buckley et al [1999]</a>, <a class="bk_pop" href="#x-scid.REF.puck.1999">Puck [1999]</a>, and unpublished data. See also <a class="bk_pop" href="#x-scid.REF.conley.1996">Conley &#x00026; Stiehm [1996]</a>.</p></div></dd><dt>1. </dt><dd><div id="x-scid.TF.1.1"><p class="no_margin">0-3 months [<a class="bk_pop" href="#x-scid.REF.buckley.2012.597">Buckley 2012</a>]</p></div></dd><dt>2. </dt><dd><div id="x-scid.TF.1.2"><p class="no_margin">Cord blood [<a class="bk_pop" href="#x-scid.REF.altman.1961">Altman 1961</a>]</p></div></dd><dt>3. </dt><dd><div id="x-scid.TF.1.3"><p class="no_margin">Individuals with atypical X-SCID caused by Arg222Cys or rare <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants may have detectable T cells [<a class="bk_pop" href="#x-scid.REF.fuchs.2014.3129">Fuchs et al 2014</a>, <a class="bk_pop" href="#x-scid.REF.okuno.2015.610">Okuno et al 2015</a>].</p></div></dd><dt>4. </dt><dd><div id="x-scid.TF.1.4"><p class="no_margin">Two individuals with low B cells (44 and 50 cells/&#x003bc;L) were considered to have X-SCID based on family history [<a class="bk_pop" href="#x-scid.REF.stephan.1993.564">Stephan et al 1993</a>].</p></div></dd></dl></div></div></div><p><b>Lymphocyte functional tests</b></p><ul><li class="half_rhythm"><div>Antibody responses to vaccines and infectious agents are absent.</div></li><li class="half_rhythm"><div>T-cell responses to mitogens and/or anti-CD3 are lacking.</div></li></ul><p><b>Immunoglobulin concentrations</b></p><ul><li class="half_rhythm"><div>Serum concentrations of IgA and IgM are low.</div></li><li class="half_rhythm"><div>Serum concentration of IgG is generally normal at birth, but declines as maternally transferred IgG disappears by age three months.</div></li></ul></div><div id="x-scid.Establishing_the_Diagnosis"><h3>Establishing the Diagnosis</h3><p>The diagnosis of X-SCID <b>is established</b> in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with identification of a <a class="def" href="/books/n/gene/glossary/def-item/hemizygous/">hemizygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>IL2RG</i> by molecular testing (see <a class="figpopup" href="/books/NBK1410/table/x-scid.T.molecular_genetic_testing_used/?report=objectonly" target="object" rid-figpopup="figxscidTmoleculargenetictestingused" rid-ob="figobxscidTmoleculargenetictestingused">Table 2</a>).</p><p>Molecular testing approaches can include <b>single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing</b>, use of a <b><a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b>, and <b>more comprehensive</b>
<b><a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b>:</p><ul><li class="half_rhythm"><div class="half_rhythm"><b>Single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing.</b> Sequence analysis of <i>IL2RG</i> is performed first followed by gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> if no <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is found.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>A <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b> that includes <i>IL2RG</i> and other genes of interest (see <a href="#x-scid.Differential_Diagnosis">Differential Diagnosis</a>) may also be considered. Note: (1) The genes included in the panel and the diagnostic <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> of the testing used for each <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this <i>GeneReview</i>; thus, clinicians need to determine which multigene panel is most likely to identify the genetic cause of the condition at the most reasonable cost while limiting identification of variants of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a> and pathogenic variants in genes that do not explain the underlying <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. (3) Methods used in a panel may include <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>, and/or other non-sequencing-based tests.</div><div class="half_rhythm">For an introduction to multigene panels click <a href="/books/n/gene/app5/#app5.Multigene_Panels">here</a>. More detailed information for clinicians ordering genetic tests can be found <a href="/books/n/gene/app5/#app5.Multigene_Panels_FAQs">here</a>.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>More comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b> (when available) including <a class="def" href="/books/n/gene/glossary/def-item/exome-sequencing/">exome sequencing</a>, <a class="def" href="/books/n/gene/glossary/def-item/genome-sequencing/">genome sequencing</a>, and mitochondrial sequencing may be considered if serial single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing (and/or use of a <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a> that contains <i>IL2RG</i>) fails to confirm a diagnosis in an individual with features of X-SCID. For an introduction to comprehensive genomic testing click <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing">here</a>. More detailed information for clinicians ordering genomic testing can be found <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing_1">here</a>.</div></li></ul><div id="x-scid.T.molecular_genetic_testing_used" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in X-Linked Severe Combined Immunodeficiency</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1410/table/x-scid.T.molecular_genetic_testing_used/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__x-scid.T.molecular_genetic_testing_used_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_x-scid.T.molecular_genetic_testing_used_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_x-scid.T.molecular_genetic_testing_used_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Test Method</th><th id="hd_h_x-scid.T.molecular_genetic_testing_used_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Proportion of Probands with a Pathogenic Variant&#x000a0;<sup>2</sup> Detectable by This Method</th></tr></thead><tbody><tr><td headers="hd_h_x-scid.T.molecular_genetic_testing_used_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><i>IL2RG</i></td><td headers="hd_h_x-scid.T.molecular_genetic_testing_used_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>3,&#x000a0;4</sup></td><td headers="hd_h_x-scid.T.molecular_genetic_testing_used_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~99%&#x000a0;<sup>5,&#x000a0;6</sup></td></tr><tr><td headers="hd_h_x-scid.T.molecular_genetic_testing_used_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>&#x000a0;<sup>7</sup></td><td headers="hd_h_x-scid.T.molecular_genetic_testing_used_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~1%&#x000a0;<sup>8</sup></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="x-scid.TF.2.1"><p class="no_margin">See <a href="/books/NBK1410/#x-scid.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>2. </dt><dd><div id="x-scid.TF.2.2"><p class="no_margin">See <a href="#x-scid.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants detected in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div></dd><dt>3. </dt><dd><div id="x-scid.TF.2.3"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>4. </dt><dd><div id="x-scid.TF.2.4"><p class="no_margin">Lack of amplification by <a class="def" href="/books/n/gene/glossary/def-item/pcr/">PCR</a> prior to <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> can suggest a putative (multi)<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> on the X <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> males; confirmation may require additional testing by <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>.</p></div></dd><dt>5. </dt><dd><div id="x-scid.TF.2.5"><p class="no_margin">Proportion of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals with a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>(s) as classified by test method [<a class="bk_pop" href="#x-scid.REF.noguchi.1993.147">Noguchi et al 1993</a>, <a class="bk_pop" href="#x-scid.REF.puck.1993.1099">Puck et al 1993</a>, <a class="bk_pop" href="#x-scid.REF.puck.1996.507">Puck 1996</a>, <a class="bk_pop" href="#x-scid.REF.puck.1997a.628">Puck et al 1997a</a>, <a class="bk_pop" href="#x-scid.REF.puck.1997b.1968">Puck et al 1997b</a>]</p></div></dd><dt>6. </dt><dd><div id="x-scid.TF.2.6"><p class="no_margin">Sequence analysis of <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> DNA cannot detect <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> of one or more exons or the entire <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> in a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> female.</p></div></dd><dt>7. </dt><dd><div id="x-scid.TF.2.7"><p class="no_margin">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> detects intragenic deletions or duplications. Methods used may include: <a class="def" href="/books/n/gene/glossary/def-item/quantitative-pcr/">quantitative PCR</a>, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted microarray designed to detect single-<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions or duplications.</p></div></dd><dt>8. </dt><dd><div id="x-scid.TF.2.8"><p class="no_margin">Deletion/<a class="def" href="/books/n/gene/glossary/def-item/duplication/">duplication</a> analysis can be used to confirm a putative <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a>/whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> in males after failure to amplify by <a class="def" href="/books/n/gene/glossary/def-item/pcr/">PCR</a> in the <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>. To date, five large deletions in <i>IL2RG</i> have been reported [<a class="bk_pop" href="#x-scid.REF.clark.1995.427">Clark et al 1995</a>, <a class="bk_pop" href="#x-scid.REF.haceinbey.1996.3108">Hacein-Bey et al 1996</a>, <a class="bk_pop" href="#x-scid.REF.niemela.2000.33">Niemela et al 2000</a>, <a class="bk_pop" href="#x-scid.REF.lee.2011.281">Lee et al 2011</a>, <a class="bk_pop" href="#x-scid.REF.zhang.2013.42">Zhang et al 2013</a>].</p></div></dd></dl></div></div></div></div></div><div id="x-scid.Clinical_Characteristics"><h2 id="_x-scid_Clinical_Characteristics_">Clinical Characteristics</h2><div id="x-scid.Clinical_Description"><h3>Clinical Description</h3><p><b>Typical <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> severe combined immunodeficiency</b>
<b>(X-SCID).</b> Affected males appear normal at birth. As transplacental transfer of maternal serum antibody concentrations decline, infants with X-SCID are increasingly prone to infection. Most infants come to medical attention between age three and six months; however, presentation with life-threatening infection prior to three months is not uncommon. With more than 75% of states participating in <a class="def" href="/books/n/gene/glossary/def-item/newborn-screening/">newborn screening</a> for SCID, a common presentation now is an asymptomatic, healthy appearing child.</p><p>Delayed diagnosis can lead to features such as failure to thrive, oral/diaper candidiasis, absent tonsils and lymph nodes, recurrent infections, infections with opportunistic organisms such as <i>Pneumocystis</i>, and persistence of infections. Additional common features include rashes, diarrhea, cough and congestion, fevers, pneumonia, sepsis, and other severe bacterial infections.</p><p>Infections that initially appear ordinary such as oral thrush, otitis media, respiratory viral infections (e.g., RSV, parainfluenza, adenovirus, influenza), and gastrointestinal diseases resulting in diarrhea may cause concern only when they persist or do not respond to usual medical management.</p><p>Less common features include the following:</p><ul><li class="half_rhythm"><div>Disseminated infections (salmonella, varicella, cytomegalovirus [CMV], Epstein-Barr virus, herpes simplex virus, BCG, and vaccine strain [live] polio virus)</div></li><li class="half_rhythm"><div>Transplacental transfer of maternal lymphocytes to the infant prenatally or during parturition that causes graft-vs-host disease (GVHD) characterized by erythematous skin rashes, hepatomegaly, and lymphadenopathy [<a class="bk_pop" href="#x-scid.REF.denianke.2001.227">Denianke et al 2001</a>]</div></li><li class="half_rhythm"><div>Recurrent bacterial meningitis</div></li><li class="half_rhythm"><div>In rare cases, neurologic features such as opisthotonus, infantile spasms, and hypsarrhythmia</div></li></ul><p><b>Atypical X-SCID.</b> Individuals with pathogenic variants that result in production of a small amount of <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a> or a protein with residual activity are less frequently seen. These individuals may have an atypical disease characterized as T<sup>+</sup>B<sup>+</sup>NK<sup>&#x02013;</sup> (in contrast to typical X-SCID, which is designated T<sup>&#x02013;</sup>B<sup>+</sup>NK<sup>&#x02013;</sup>). It is critical to perform functional testing when atypical X-SCID is suspected.</p><p>These individuals may have immune dysregulation and autoimmunity associated with rashes, splenomegaly, gastrointestinal malabsorption, and/or short stature [<a class="bk_pop" href="#x-scid.REF.disanto.1994.9466">DiSanto et al 1994</a>, <a class="bk_pop" href="#x-scid.REF.schmalstieg.1995.1169">Schmalstieg et al 1995</a>, <a class="bk_pop" href="#x-scid.REF.morelon.1996.1708">Morelon et al 1996</a>, <a class="bk_pop" href="#x-scid.REF.stephan.1996.1563">Stephan et al 1996</a>, <a class="bk_pop" href="#x-scid.REF.fuchs.2014.3129">Fuchs et al 2014</a>].</p><p>Additionally, rare cases of somatic reversion events resulting in a later-onset combined immunodeficiency in males inheriting a pathogenic <i>IL2RG</i> <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> have been reported [<a class="bk_pop" href="#x-scid.REF.okuno.2015.610">Okuno et al 2015</a>].</p></div><div id="x-scid.GenotypePhenotype_Correlations"><h3>Genotype-Phenotype Correlations</h3><p>Most pathogenic variants causing typical X-SCID are functionally <a class="def" href="/books/n/gene/glossary/def-item/null/">null</a>.</p><p>Individuals with a <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> or other potentially non-<a class="def" href="/books/n/gene/glossary/def-item/loss-of-function/">loss-of-function</a> variant may have atypical X-SCID.</p></div><div id="x-scid.Prevalence"><h3>Prevalence</h3><p>The incidence of X-SCID is unknown; it is estimated to be at least 1:50,000-100,000 births.</p><p>Individuals from all ethnic groups are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> in equal frequency. Because of population structure, X-SCID may account for a larger proportion of individuals with all types of SCID in the United States than in Europe.</p></div></div><div id="x-scid.Genetically_Related_Allelic_Disor"><h2 id="_x-scid_Genetically_Related_Allelic_Disor_">Genetically Related (Allelic) Disorders</h2><p>No phenotypes other than those discussed in this <i>GeneReview</i> are known to be associated with pathogenic variants in <i>IL2RG</i>.</p></div><div id="x-scid.Differential_Diagnosis"><h2 id="_x-scid_Differential_Diagnosis_">Differential Diagnosis</h2><p><b>Severe combined immunodeficiency (SCID)</b> can be classified by the nature of T, B, and NK lymphocyte numbers and function (<a class="figpopup" href="/books/NBK1410/table/x-scid.T.types_of_classic_severe_combine/?report=objectonly" target="object" rid-figpopup="figxscidTtypesofclassicseverecombine" rid-ob="figobxscidTtypesofclassicseverecombine">Table 3</a>). Presence of each subclass of lymphocytes in most individuals of each <a class="def" href="/books/n/gene/glossary/def-item/genotype/">genotype</a> is indicated by (+); absence by (&#x02013;). Since the implementation of <a class="def" href="/books/n/gene/glossary/def-item/newborn-screening/">newborn screening</a> the incidence of each SCID type has become clearer; however, X-SCID remains one of the most common forms of SCID [<a class="bk_pop" href="#x-scid.REF.kwan.2014.729">Kwan et al 2014</a>]. The clinical presentation of X-SCID, <i>JAK3</i>-SCID, and <i>IL7R</i>-SCID is identical. In X-SCID, only males are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>; in <i>JAK3</i>- and <i>IL7R</i>-SCID, both males and females are affected.</p><div id="x-scid.T.types_of_classic_severe_combine" class="table"><h3><span class="label">Table 3. </span></h3><div class="caption"><p>Types of Classic Severe Combined Immunodeficiency (SCID)</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1410/table/x-scid.T.types_of_classic_severe_combine/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__x-scid.T.types_of_classic_severe_combine_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_x-scid.T.types_of_classic_severe_combine_1_1_1_1" rowspan="2" scope="col" colspan="1" headers="hd_h_x-scid.T.types_of_classic_severe_combine_1_1_1_1" style="text-align:left;vertical-align:middle;">Disorder</th><th id="hd_h_x-scid.T.types_of_classic_severe_combine_1_1_1_2" rowspan="2" scope="col" colspan="1" headers="hd_h_x-scid.T.types_of_classic_severe_combine_1_1_1_2" style="text-align:left;vertical-align:middle;">Gene(s)</th><th id="hd_h_x-scid.T.types_of_classic_severe_combine_1_1_1_3" colspan="3" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Lymphocyte Phenotype</th><th id="hd_h_x-scid.T.types_of_classic_severe_combine_1_1_1_4" rowspan="2" scope="col" colspan="1" headers="hd_h_x-scid.T.types_of_classic_severe_combine_1_1_1_4" style="text-align:left;vertical-align:middle;">MOI</th><th id="hd_h_x-scid.T.types_of_classic_severe_combine_1_1_1_5" rowspan="2" scope="col" colspan="1" headers="hd_h_x-scid.T.types_of_classic_severe_combine_1_1_1_5" style="text-align:left;vertical-align:middle;">Comments</th></tr><tr><th headers="hd_h_x-scid.T.types_of_classic_severe_combine_1_1_1_3" id="hd_h_x-scid.T.types_of_classic_severe_combine_1_1_2_1" colspan="1" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">T</th><th headers="hd_h_x-scid.T.types_of_classic_severe_combine_1_1_1_3" id="hd_h_x-scid.T.types_of_classic_severe_combine_1_1_2_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">B</th><th headers="hd_h_x-scid.T.types_of_classic_severe_combine_1_1_1_3" id="hd_h_x-scid.T.types_of_classic_severe_combine_1_1_2_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">NK</th></tr></thead><tbody><tr><td headers="hd_h_x-scid.T.types_of_classic_severe_combine_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">X-SCID</td><td headers="hd_h_x-scid.T.types_of_classic_severe_combine_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>IL2RG</i></td><td headers="hd_h_x-scid.T.types_of_classic_severe_combine_1_1_1_3 hd_h_x-scid.T.types_of_classic_severe_combine_1_1_2_1" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;">&#x02013;</td><td headers="hd_h_x-scid.T.types_of_classic_severe_combine_1_1_1_3 hd_h_x-scid.T.types_of_classic_severe_combine_1_1_2_2" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_x-scid.T.types_of_classic_severe_combine_1_1_1_3 hd_h_x-scid.T.types_of_classic_severe_combine_1_1_2_3" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;">&#x02013;</td><td headers="hd_h_x-scid.T.types_of_classic_severe_combine_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">XLR</td><td headers="hd_h_x-scid.T.types_of_classic_severe_combine_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_x-scid.T.types_of_classic_severe_combine_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>JAK3</i>-SCID (OMIM <a href="http://omim.org/entry/600802" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">600802</a>)</td><td headers="hd_h_x-scid.T.types_of_classic_severe_combine_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>JAK3</i></td><td headers="hd_h_x-scid.T.types_of_classic_severe_combine_1_1_1_4" colspan="1" rowspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_x-scid.T.types_of_classic_severe_combine_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_x-scid.T.types_of_classic_severe_combine_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>IL7R</i>-SCID (OMIM <a href="http://omim.org/entry/608971" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">608971</a>)</td><td headers="hd_h_x-scid.T.types_of_classic_severe_combine_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>IL7R</i></td><td headers="hd_h_x-scid.T.types_of_classic_severe_combine_1_1_1_3 hd_h_x-scid.T.types_of_classic_severe_combine_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02013;</td><td headers="hd_h_x-scid.T.types_of_classic_severe_combine_1_1_1_3 hd_h_x-scid.T.types_of_classic_severe_combine_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_x-scid.T.types_of_classic_severe_combine_1_1_1_3 hd_h_x-scid.T.types_of_classic_severe_combine_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_x-scid.T.types_of_classic_severe_combine_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_x-scid.T.types_of_classic_severe_combine_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_x-scid.T.types_of_classic_severe_combine_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">CD45 deficiency (OMIM <a href="http://omim.org/entry/608971" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">608971</a>)</td><td headers="hd_h_x-scid.T.types_of_classic_severe_combine_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>PTPRC</i> (previously <i>CD45)</i></td><td headers="hd_h_x-scid.T.types_of_classic_severe_combine_1_1_1_3 hd_h_x-scid.T.types_of_classic_severe_combine_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02013;</td><td headers="hd_h_x-scid.T.types_of_classic_severe_combine_1_1_1_3 hd_h_x-scid.T.types_of_classic_severe_combine_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_x-scid.T.types_of_classic_severe_combine_1_1_1_3 hd_h_x-scid.T.types_of_classic_severe_combine_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+/&#x02013;</td><td headers="hd_h_x-scid.T.types_of_classic_severe_combine_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_x-scid.T.types_of_classic_severe_combine_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_x-scid.T.types_of_classic_severe_combine_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/ada/">Adenosine deaminase deficiency</a></td><td headers="hd_h_x-scid.T.types_of_classic_severe_combine_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>ADA</i></td><td headers="hd_h_x-scid.T.types_of_classic_severe_combine_1_1_1_3 hd_h_x-scid.T.types_of_classic_severe_combine_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02013;</td><td headers="hd_h_x-scid.T.types_of_classic_severe_combine_1_1_1_3 hd_h_x-scid.T.types_of_classic_severe_combine_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02013;</td><td headers="hd_h_x-scid.T.types_of_classic_severe_combine_1_1_1_3 hd_h_x-scid.T.types_of_classic_severe_combine_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02013;</td><td headers="hd_h_x-scid.T.types_of_classic_severe_combine_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_x-scid.T.types_of_classic_severe_combine_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Delayed SCID if ADA deficiency is partial</td></tr><tr><td headers="hd_h_x-scid.T.types_of_classic_severe_combine_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;">RAG-deficient SCID (OMIM <a href="http://omim.org/entry/601457" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">601457</a>)</td><td headers="hd_h_x-scid.T.types_of_classic_severe_combine_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>RAG1</i></td><td headers="hd_h_x-scid.T.types_of_classic_severe_combine_1_1_1_3 hd_h_x-scid.T.types_of_classic_severe_combine_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02013;</td><td headers="hd_h_x-scid.T.types_of_classic_severe_combine_1_1_1_3 hd_h_x-scid.T.types_of_classic_severe_combine_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02013;</td><td headers="hd_h_x-scid.T.types_of_classic_severe_combine_1_1_1_3 hd_h_x-scid.T.types_of_classic_severe_combine_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_x-scid.T.types_of_classic_severe_combine_1_1_1_4" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_x-scid.T.types_of_classic_severe_combine_1_1_1_5" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;">"Leaky SCID" due to <a class="def" href="/books/n/gene/glossary/def-item/hypomorphic/">hypomorphic</a> alleles&#x000a0;<sup>1</sup>, increasingly detected w/<a class="def" href="/books/n/gene/glossary/def-item/newborn-screening/">newborn screening</a>&#x000a0;<sup>2</sup></td></tr><tr><td headers="hd_h_x-scid.T.types_of_classic_severe_combine_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;"><i>RAG2</i></td><td headers="hd_h_x-scid.T.types_of_classic_severe_combine_1_1_1_3 hd_h_x-scid.T.types_of_classic_severe_combine_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02013;</td><td headers="hd_h_x-scid.T.types_of_classic_severe_combine_1_1_1_3 hd_h_x-scid.T.types_of_classic_severe_combine_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02013;</td><td headers="hd_h_x-scid.T.types_of_classic_severe_combine_1_1_1_3 hd_h_x-scid.T.types_of_classic_severe_combine_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td></tr><tr><td headers="hd_h_x-scid.T.types_of_classic_severe_combine_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">SCID Athabaskan (OMIM <a href="http://omim.org/entry/602450" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">602450</a>)</td><td headers="hd_h_x-scid.T.types_of_classic_severe_combine_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>DCLRE1C</i></td><td headers="hd_h_x-scid.T.types_of_classic_severe_combine_1_1_1_3 hd_h_x-scid.T.types_of_classic_severe_combine_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02013;</td><td headers="hd_h_x-scid.T.types_of_classic_severe_combine_1_1_1_3 hd_h_x-scid.T.types_of_classic_severe_combine_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02013;</td><td headers="hd_h_x-scid.T.types_of_classic_severe_combine_1_1_1_3 hd_h_x-scid.T.types_of_classic_severe_combine_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_x-scid.T.types_of_classic_severe_combine_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_x-scid.T.types_of_classic_severe_combine_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">10% <a class="def" href="/books/n/gene/glossary/def-item/carrier-rate/">carrier rate</a> among Athabaskan-speaking Native Americans (e.g., Navajo, Apache)</td></tr><tr><td headers="hd_h_x-scid.T.types_of_classic_severe_combine_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">TCR deficiency</td><td headers="hd_h_x-scid.T.types_of_classic_severe_combine_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>CD3D, CD3E, CD247</i></td><td headers="hd_h_x-scid.T.types_of_classic_severe_combine_1_1_1_3 hd_h_x-scid.T.types_of_classic_severe_combine_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02013;/Low</td><td headers="hd_h_x-scid.T.types_of_classic_severe_combine_1_1_1_3 hd_h_x-scid.T.types_of_classic_severe_combine_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_x-scid.T.types_of_classic_severe_combine_1_1_1_3 hd_h_x-scid.T.types_of_classic_severe_combine_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_x-scid.T.types_of_classic_severe_combine_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_x-scid.T.types_of_classic_severe_combine_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Rare</td></tr><tr><td headers="hd_h_x-scid.T.types_of_classic_severe_combine_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNAPKCS deficiency (OMIM <a href="http://omim.org/entry/615966" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">615966</a>)</td><td headers="hd_h_x-scid.T.types_of_classic_severe_combine_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>PRKDC</i></td><td headers="hd_h_x-scid.T.types_of_classic_severe_combine_1_1_1_3 hd_h_x-scid.T.types_of_classic_severe_combine_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02013;</td><td headers="hd_h_x-scid.T.types_of_classic_severe_combine_1_1_1_3 hd_h_x-scid.T.types_of_classic_severe_combine_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02013;</td><td headers="hd_h_x-scid.T.types_of_classic_severe_combine_1_1_1_3 hd_h_x-scid.T.types_of_classic_severe_combine_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_x-scid.T.types_of_classic_severe_combine_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_x-scid.T.types_of_classic_severe_combine_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Rare</td></tr><tr><td headers="hd_h_x-scid.T.types_of_classic_severe_combine_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reticular dysgenesis (OMIM <a href="http://omim.org/entry/267500" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">267500</a>)</td><td headers="hd_h_x-scid.T.types_of_classic_severe_combine_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>AK2</i></td><td headers="hd_h_x-scid.T.types_of_classic_severe_combine_1_1_1_3 hd_h_x-scid.T.types_of_classic_severe_combine_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02013;</td><td headers="hd_h_x-scid.T.types_of_classic_severe_combine_1_1_1_3 hd_h_x-scid.T.types_of_classic_severe_combine_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02013;</td><td headers="hd_h_x-scid.T.types_of_classic_severe_combine_1_1_1_3 hd_h_x-scid.T.types_of_classic_severe_combine_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02013;</td><td headers="hd_h_x-scid.T.types_of_classic_severe_combine_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_x-scid.T.types_of_classic_severe_combine_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Rare</td></tr><tr><td headers="hd_h_x-scid.T.types_of_classic_severe_combine_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">CORO1a deficiency (OMIM <a href="http://omim.org/entry/615401" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">615401</a>)</td><td headers="hd_h_x-scid.T.types_of_classic_severe_combine_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>CORO1A</i></td><td headers="hd_h_x-scid.T.types_of_classic_severe_combine_1_1_1_3 hd_h_x-scid.T.types_of_classic_severe_combine_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02013;/Low</td><td headers="hd_h_x-scid.T.types_of_classic_severe_combine_1_1_1_3 hd_h_x-scid.T.types_of_classic_severe_combine_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+/&#x02013;</td><td headers="hd_h_x-scid.T.types_of_classic_severe_combine_1_1_1_3 hd_h_x-scid.T.types_of_classic_severe_combine_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+/&#x02013;</td><td headers="hd_h_x-scid.T.types_of_classic_severe_combine_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_x-scid.T.types_of_classic_severe_combine_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Rare</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">AR = <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a>; MOI = <a class="def" href="/books/n/gene/glossary/def-item/mode-of-inheritance/">mode of inheritance</a>; XLR = <a class="def" href="/books/n/gene/glossary/def-item/x-linked-recessive/">X-linked recessive</a></p></div></dd><dt></dt><dd><div><p class="no_margin">Molecular causes of SCID based on the International Union of Immunological Societies expert committee for primary immunodeficiency</p></div></dd><dt>1. </dt><dd><div id="x-scid.TF.3.1"><p class="no_margin">See following: <b>Newborn screening</b> &#x02013; <b>Leaky SCID</b>.</p></div></dd><dt>2. </dt><dd><div id="x-scid.TF.3.2"><p class="no_margin"><a class="bk_pop" href="#x-scid.REF.kwan.2014.729">Kwan et al [2014]</a></p></div></dd></dl></div></div></div><p>Note: A growing list of rare causes of SCID-like phenotypes include pathogenic variants in the following additional genes: <i>CD3G</i>, <i>CD8A</i>, <i>CHD7</i>, <i>CIITA</i>, <i>DOCK8</i>, <i>FOXN1</i>, <i>LCK</i>, <i>LIG4</i>, <i>MTHFD1</i>, <i>NBS1</i>, <i>NHEJ1</i>, <i>ORAI1</i>, <i>PCFT</i>, <i>PGM3</i>, <i>PNP</i>, <i>PRKDC</i>, <i>RFX-B</i>, <i>RFXANK</i>, <i>RFX5</i>, <i>RFXAP</i>, <i>RMRP</i>, <i>STIM1</i>, <i>TBX1</i>, <i>TTC7A</i>, <a href="/books/n/gene/zap70-scid/"><i>ZAP70</i></a>.</p><p><b>Newborn screening</b> results can show low or absent TRECs and clinically significant T lymphocytopenia (&#x0003c;1500 T cells/&#x003bc;L) in numerous conditions (adapted from criteria from <a class="bk_pop" href="#x-scid.REF.puck.2012.607">Puck [2012]</a>):</p><ul><li class="half_rhythm"><div><b>Typical SCID.</b> &#x0003c;300 autologous T cells/&#x003bc;L and &#x0003c;10% of normal proliferation to the mitogen PHA</div></li><li class="half_rhythm"><div><b>Leaky SCID.</b> 300 to 1500 autologous T cells/&#x003bc;L and impaired but not absent (10%-30% of normal) proliferation to the mitogen PHA caused by a <a class="def" href="/books/n/gene/glossary/def-item/hypomorphic/">hypomorphic</a> <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> (partial loss of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> function) in a typical SCID-related gene</div></li><li class="half_rhythm"><div><b>Variant SCID.</b> No defect in a known SCID-related <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and 300 to 1500 autologous T cells/&#x003bc;L with impaired function</div></li><li class="half_rhythm"><div>Syndromes with variably <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> cellular immunity that may be severe, such as <a href="/books/n/gene/gr_22q11deletion/">DiGeorge syndrome</a>, <a href="/books/n/gene/charge/">CHARGE syndrome</a>, Jacobsen syndrome, <i>RAC2</i>-dominant interfering variant, DOCK8-deficient hyper IgE syndrome, and <a href="/books/n/gene/chh/">cartilage-hair hypoplasia</a></div></li><li class="half_rhythm"><div>Transient lymphopenia and abnormal TREC screening associated with prematurity (&#x0003c;37 weeks adjusted gestational age). Repeat testing is warranted.</div></li></ul><p>Not all T-cell disorders are detected with the TREC test despite the presence of impaired immune function. For example, individuals with MHC class II deficiency still retain CD8+ T cells and <a href="/books/n/gene/zap70-scid/">ZAP70 deficiency</a> presents with very a high CD4/CD8 ratio. These individuals can present with a SCID-like <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>.</p><p><b>Other <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> immunodeficiencies</b> include <a href="/books/n/gene/xla/">X-linked agammaglobulinemia</a>, <a href="/books/n/gene/was/">Wiskott-Aldrich syndrome</a>, <a href="/books/n/gene/xlhi/">X-linked hyper-IgM syndrome</a>, <a href="/books/n/gene/x-lpd/">X-linked lymphoproliferative disease</a>, NEMO (X-linked ectodermal dysplasia with varying immunodeficiency) (see <a href="/books/n/gene/i-p/">Incontinentia Pigmenti</a>), <a href="/books/n/gene/ipex/">IPEX</a> (autoimmunity, polyendocrinopathy, enteropathy), <a href="/books/n/gene/cgd/">chronic granulomatous disease</a> (CGD), and properdin deficiency (OMIM <a href="http://omim.org/entry/312060" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">312060</a>).</p><p><b>Human immunodeficiency virus (HIV).</b> Infants with HIV may also have recurrent and opportunistic infections and failure to thrive. They have evidence of HIV virus by p24 antigen testing or <a class="def" href="/books/n/gene/glossary/def-item/pcr/">PCR</a> testing. In contrast to T cells in SCID, T cells in HIV are generally present although absolute T-cell numbers can be markedly reduced in some individuals.</p></div><div id="x-scid.Management"><h2 id="_x-scid_Management_">Management</h2><div id="x-scid.Evaluations_Following_Initial_Dia"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease and needs of an individual diagnosed with <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> severe combined immunodeficiency (X-SCID), the following evaluations are recommended:</p><ul><li class="half_rhythm"><div>History, including family history, growth and development, and localized and generalized infectious processes (e.g., diarrhea, failure to thrive, pneumonia, sepsis, viral and fungal infections)</div></li><li class="half_rhythm"><div>CBC and differential count to document absolute lymphocyte count, if not performed in the diagnostic work up</div></li><li class="half_rhythm"><div>Flow cytometric determination of T-cell, B-cell, and NK-cell numbers, if not performed in the diagnostic work up</div></li><li class="half_rhythm"><div>In vitro mitogen assay of mononuclear cells (using PHA, ConA, or PWM) and soluble antigens (<i>Candida</i> antigen, tetanus toxoid). Rarely, pathogenic variants in the TCR pathway can alter the ability to proliferate after stimulation in response to anti-CD3 stimulation, despite normal numbers of T lymphocytes.</div></li><li class="half_rhythm"><div>Functional screening of STAT3 phosphorylation after IL-21 stimulation to test functionality of the common-gamma chain</div></li><li class="half_rhythm"><div>Consultation with a specialist in immunodeficiency</div></li><li class="half_rhythm"><div>Consultation with a clinical geneticist and/or genetic counselor</div></li></ul></div><div id="x-scid.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><p>The current goals of treatment include prophylaxis for infections and preemptive bone marrow transplant (BMT) prior to the development of symptoms (see <a href="#x-scid.Prevention_of_Primary_Manifestati">Prevention of Primary Manifestations</a>).</p><ul><li class="half_rhythm"><div>An individual diagnosed with X-SCID requires emergent treatment to provide a functional immune system.</div></li><li class="half_rhythm"><div>Interim management includes treatment of infections and use of immunoglobulin infusions and antibiotics, particularly prophylaxis against <i>Pneumocystis jirovecii</i> (formerly <i>Pneumocystis carinii</i>) and, in most cases, fungal infections.</div></li><li class="half_rhythm"><div>Isolation from exposure to CMV (breast milk, young children, blood products) is indicated.</div></li></ul></div><div id="x-scid.Prevention_of_Primary_Manifestati"><h3>Prevention of Primary Manifestations</h3><p><b>Bone marrow transplantation (BMT).</b> Prompt immune reconstitution is required for survival of children with X-SCID [<a class="bk_pop" href="#x-scid.REF.myers.2002.872">Myers et al 2002</a>]. BMT was first successful in 1968 and remains the standard means of immune reconstitution. The general experience is that genotypically HLA-identical marrow transplantation restores T-cell immunity in more than 90% of unconditioned individuals with SCID, although B-cell reconstitution occurs in only a limited subset of these individuals [<a class="bk_pop" href="#x-scid.REF.oreilly.1989.273">O'Reilly et al 1989</a>, <a class="bk_pop" href="#x-scid.REF.buckley.1999.508">Buckley et al 1999</a>].</p><p>Although many centers have expertise in performing bone marrow transplantation in individuals with malignancy, the special issues arising in bone marrow transplantation for X-SCID require involvement of immunodeficiency specialists for an optimal outcome. Individuals with SCID have no immune system capable of rejecting the graft and, therefore, do not typically require fully ablative conditioning; regimens that do not employ agents at doses resulting in long-lasting marrow aplasia are referred to as reduced-intensity conditioning (RIC) regimens. Additionally, protocols including alpha/beta T-cell depletion in graft preparations are now being used to improve unrelated donor graft outcomes.</p><ul><li class="half_rhythm"><div>HLA-matched bone marrow transplantation from a relative is preferred; however, most individuals lack a matched, related donor.</div></li><li class="half_rhythm"><div>For infants who do not have a matched, related donor, haploidentical parental bone marrow that has been depleted of mature T cells can be used [<a class="bk_pop" href="#x-scid.REF.buckley.1999.508">Buckley et al 1999</a>, <a class="bk_pop" href="#x-scid.REF.pai.2014.434">Pai et al 2014</a>]. In this technique, the bone marrow is depleted of T cells in order to remove mismatched T cells, which would react against the baby's tissues and cause graft versus host disease (GVHD).</div></li><li class="half_rhythm"><div>Matched, unrelated donor transplantation of peripherally harvested bone marrow (or less frequently cord blood hematopoietic stem cells) in association with partially myeloablative or RIC regimens is now being used at specialized transplantation centers, although GVHD can be a significant problem in some individuals.</div></li></ul><p>Mismatched T cells can react against the baby's tissues and cause GVHD. Cord blood from normal infants is now being banked; frozen cells can be thawed and used in other unrelated donor transplants.</p><p>The best timing for BMT is immediately after birth because young infants are less likely than older infants to have had serious infections or failure to thrive. The Primary Immune Deficiency Treatment Consortium (PIDTC) found in 25 centers over the last decade significantly better outcomes (&#x0003e;90% survival) in children receiving transplantation in early infancy (age &#x0003c;3.5 months) without prior infections even after alternative donor grafts were used [<a class="bk_pop" href="#x-scid.REF.pai.2014.434">Pai et al 2014</a>]. Younger infants also have more rapid engraftment, fewer post-transplantation infections, less GVHD, and shorter hospitalizations than those in whom BMT is delayed [<a class="bk_pop" href="#x-scid.REF.kane.2001.f110">Kane et al 2001</a>, <a class="bk_pop" href="#x-scid.REF.myers.2002.872">Myers et al 2002</a>]. The optimal age and RIC regimen in young infants, however, remains to be determined. BMT after age 3.5 months and/or a history of infections resulted in a dramatic decrease in survival post transplantation.</p><p>Complications following BMT in some individuals include GVHD, failure to make adequate antibodies requiring long-term immunoglobulin replacement, late loss of T cells presumably due to failure to engraft hematopoietic stem cells, chronic warts, and lymphocyte dysregulation.</p><p><b>Administration of immunoglobulin.</b> Long-term periodic administration of immunoglobulin may be required in those who fail to develop allogeneic, functional B lymphocytes after transplantation.</p><p><b>Gene therapy.</b> Gene therapy has been evaluated in individuals not eligible for BMT, after failed BMT, and in individuals with only haploidentical donors. Gene therapy performed using autologous bone marrow stem/progenitor cells transduced with gamma-retroviral vectors expressing a therapeutic <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> resulted in significant T-cell reconstitution in the majority of young infants with X-SCID, but only limited success in those with severe infections at the time of transplantation [reviewed in <a class="bk_pop" href="#x-scid.REF.fischer.2011.1356">Fischer et al 2011</a>, <a class="bk_pop" href="#x-scid.REF.haceinbeyabina.2014.1407">Hacein-Bey-Abina et al 2014</a>].</p><ul><li class="half_rhythm"><div>B-cell reconstitution was less consistent with roughly half being able to discontinue gamma-globulin replacement therapy.</div></li><li class="half_rhythm"><div>Unfortunately, between two early trials, five of 20 individuals developed leukemia-like disease requiring ALL-type therapy due to retroviral insertional activation of cellular growth regulatory genes [<a class="bk_pop" href="#x-scid.REF.howe.2008.3143">Howe et al 2008</a>, <a class="bk_pop" href="#x-scid.REF.haceinbeyabina.2010.355">Hacein-Bey-Abina et al 2010</a>, <a class="bk_pop" href="#x-scid.REF.deichmann.2011.2031">Deichmann et al 2011</a>]. Newer, second-generation vectors utilizing self-<a class="def" href="/books/n/gene/glossary/def-item/inactivating/">inactivating</a> (SIN) gamma-retroviral vectors have shown similar efficacy in T-cell reconstitution with improved safety design, no adverse events reported in nine individuals over three years post transplantation, and significantly fewer insertions found in genes implicated in lymphoproliferation [<a class="bk_pop" href="#x-scid.REF.haceinbeyabina.2014.1407">Hacein-Bey-Abina et al 2014</a>]. Clinical trials using an SIN-lentiviral vector in conjunction with busulfan-based partial myeloablative conditioning are underway for both infants and older individuals who have failed BMT. Initial results in a small number of older individuals have demonstrated sustained myeloid viral marking and restoration of T, B, and NK cell numbers and function [Author, personal communication].</div></li></ul><p>See also <a href="#x-scid.Therapies_Under_Investigation">Therapies Under Investigation</a>.</p></div><div id="x-scid.Prevention_of_Secondary_Complicat"><h3>Prevention of Secondary Complications</h3><p>Complications following BMT in some individuals include GVHD, failure to make adequate antibodies requiring long-term immunoglobulin replacement, late loss of T cells (presumably due to failure to engraft hematopoietic stem cells), chronic warts, lymphocyte dysregulation, and rarely, malignancy. All individuals have some degree of immunodeficiency, especially during the first six to 12 months following transplantation. PJP, viral and encapsulated organism prophylaxis should be applied per transplantation protocols. IVIG prophylaxis should be considered to maintain serum IgG levels above 400mg/dL. Prompt evaluation of illness should occur until the individual is deemed immunologically competent. Individuals with primary immunodeficiency post transplantation will require bacteriophage testing off all immunosuppressive therapy to determine eligibility for re-vaccination. Only CMV-negative, irradiated blood products should be used. Avoid breast feeding and exposure to young children to prevent CMV transmission to babies with X-SCID.</p></div><div id="x-scid.Surveillance"><h3>Surveillance</h3><p>After successful bone marrow transplantation, routine evaluation of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> boys every six to 12 months is appropriate to monitor donor cell engraftment, growth, immune and lung function, and gastrointestinal and dermatologic issues.</p></div><div id="x-scid.AgentsCircumstances_to_Avoid"><h3>Agents/Circumstances to Avoid</h3><p>The following should be avoided:</p><ul><li class="half_rhythm"><div>Live vaccines. All immunizations should be deferred until after restoration of immunocompetence.</div></li><li class="half_rhythm"><div>Transfusion of non-irradiated blood products. Only CMV-negative, irradiated (1500 to 5000 RADS) blood products should be used.</div></li><li class="half_rhythm"><div>Breast-feeding and breast milk, until maternal CMV status is established by CMV DNA <a class="def" href="/books/n/gene/glossary/def-item/pcr/">PCR</a> testing of a blood sample. CMV is a chronic infection and intermittent viral shedding in various bodily fluids occurs unpredictably. If such testing is negative and the mother is CMV serology negative, breast milk may rarely be considered safe for feeding. Frequent retesting of breast milk is required given the risk of primary infection in the mother. Pasteurization of breast milk remains controversial in preparation for BMT given the severe negative consequences in BMT outcomes.</div></li><li class="half_rhythm"><div>Exposure to young children, sick contacts, or individuals with cold sores</div></li></ul></div><div id="x-scid.Evaluation_of_Relatives_at_Risk"><h3>Evaluation of Relatives at Risk</h3><p>It is appropriate to clarify the genetic status of apparently asymptomatic at-risk male relatives of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> of the <i>IL2RG</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in the family in order to identify as early as possible those who would benefit from prompt initiation of treatment and preventive measures.</p><p>When the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in the family is known, <a class="def" href="/books/n/gene/glossary/def-item/prenatal-diagnosis/">prenatal diagnosis</a> of at-risk males allows preparation for bone marrow transplantation to be initiated before birth. Most couples at risk of having an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> male have desired prenatal testing to help prepare for optimal treatment of an affected newborn: bone marrow transplantation centers were chosen, HLA testing of family members and the prenatal sample was carried out, and a search for a marrow donor could be initiated [<a class="bk_pop" href="#x-scid.REF.puck.1997a.628">Puck et al 1997a</a>].</p><p>See <a href="#x-scid.Related_Genetic_Counseling_Issues">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="x-scid.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p>The following investigations are underway:</p><ul><li class="half_rhythm"><div>Second-generation <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> replacement strategies based on self-<a class="def" href="/books/n/gene/glossary/def-item/inactivating/">inactivating</a> (SIN) gamma-retroviral (RV) and lentiviral (LV) vectors lacking the LTR enhancers with high insertional genotoxicity are in early clinical development (see <a href="http://www.clinicaltrials.gov" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a>), and similar strategies based on self-inactivating foamy viral vectors are in pre-clinical development.</div></li><li class="half_rhythm"><div>Multi-institutional Phase I/II trials using an SIN RV vector carrying the IL2Rgamma <a class="def" href="/books/n/gene/glossary/def-item/cdna/">cDNA</a> have recently completed enrollment for infants with X-SCID performed without conditioning. Using the same SIN RV vector, the NIH has enrolled older males with X-SCID who had prior transplantation but did not achieve satisfactory immune reconstitution for a clinical trial using reduced-intensity conditioning.</div></li><li class="half_rhythm"><div>St Jude Children's Research Hospital and Seattle Children's Hospital are enrolling infants with X-SCID and the NIH is enrolling older males who had prior transplantation in SIN LV clinical trials using low dose busulfan conditioning.</div></li><li class="half_rhythm"><div>The PIDTC is developing a clinical trial assessing the impact of busulfan dose escalation in infants receiving marrow transplantation in classic SCID. This work may provide new information regarding optimal conditioning regimens for transplant and/or <a class="def" href="/books/n/gene/glossary/def-item/gene-therapy/">gene therapy</a>.</div></li></ul><p>Thus, it is anticipated that over the next several years, <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> transfer therapies with improved safety and efficacy profiles will become increasingly available.</p><p>Search <a href="http://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.clinicaltrialsregister.eu/ctr-search/search" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">EU Clinical Trials Register</a> in Europe for access to information on clinical studies for a wide range of diseases and conditions.</p></div></div><div id="x-scid.Genetic_Counseling"><h2 id="_x-scid_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="x-scid.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p><a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> severe combined immunodeficiency (X-SCID) is inherited in an X-linked manner.</p></div><div id="x-scid.Risk_to_Family_Members"><h3>Risk to Family Members</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The father of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> male will not have the disorder nor will he be <a class="def" href="/books/n/gene/glossary/def-item/hemizygous/">hemizygous</a> for the <i>IL2RG</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>; therefore, he does not require further evaluation/testing.</div></li><li class="half_rhythm"><div>In a family with more than one <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual, the mother of an affected male is an <a class="def" href="/books/n/gene/glossary/def-item/obligate-heterozygote/">obligate heterozygote</a> (<a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>). Note: If a woman has more than one affected son and the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> cannot be detected in DNA extracted from her leukocytes, she has <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a>. Female germline mosaicism has been documented in X-SCID [<a class="bk_pop" href="#x-scid.REF.omarcaigh.1997.29">O'Marcaigh et al 1997</a>].</div></li><li class="half_rhythm"><div>If a male is the only <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member (i.e., a <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> case), the mother may be a <a class="def" href="/books/n/gene/glossary/def-item/heterozygote/">heterozygote</a> (<a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>) or the affected male may have a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a>
<i>IL2RG</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, in which case the mother is not a carrier. More than half of affected males have no family history of early deaths in maternally related affected males [<a class="bk_pop" href="#x-scid.REF.puck.1997b.1968">Puck et al 1997b</a>].</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The risk to sibs depends on the genetic status of the mother:</p><ul><li class="half_rhythm"><div>If the mother of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> has an <i>IL2RG</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, the chance of transmitting the variant in each pregnancy is 50%. Males who inherit the pathogenic variant will be <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>; females who inherit the pathogenic variant will be heterozygotes (carriers) and will not be affected.</div></li><li class="half_rhythm"><div>If the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> represents a <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> case (i.e., a single occurrence in a family) and if the <i>IL2RG</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> cannot be detected in the leukocyte DNA of the mother, the sibs are still at increased risk because of the possibility of maternal <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a>. Germline mosaicism has been demonstrated in this condition [<a class="bk_pop" href="#x-scid.REF.omarcaigh.1997.29">O'Marcaigh et al 1997</a>].</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> Males with X-SCID will pass the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> to all of their daughters, who will be (heterozygotes) carriers, and to none of their sons.</p><p><b>Other family members.</b> The <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s maternal aunts may be at risk of being heterozygotes (carriers) for the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, and the aunts' offspring, depending on their gender, may be at risk of being heterozygotes (carriers) for the pathogenic variant or of being <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>.</p><p>Note: Molecular genetic testing can often determine the family member in whom a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> arose, information that could help determine genetic risk status of the extended family.</p></div><div id="x-scid.Heterozygote_Carrier_Detection"><h3>Heterozygote (Carrier) Detection</h3><p>Molecular genetic testing of at-risk female relatives to determine their genetic status is most informative if the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has been identified in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</p><p>Note: (1) Females who are <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> (carriers) for this <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> disorder are asymptomatic. (2) Identification of female heterozygotes requires either (a) prior identification of the <i>IL2RG</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in the family or, (b) if an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> male is not available for testing, <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> first by <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, and if no pathogenic variant is identified, by <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>.</p></div><div id="x-scid.Related_Genetic_Counseling_Issues"><h3>Related Genetic Counseling Issues</h3><p>See <a href="#x-scid.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</a> for information on <a class="def" href="/books/n/gene/glossary/def-item/prenatal-diagnosis/">prenatal diagnosis</a> of at-risk males to allow preparation for bone marrow transplantation.</p><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk, clarification of genetic status of at-risk females, and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>, are heterozygotes (carriers), or are at increased risk of being heterozygotes (carriers) or affected.</div></li></ul><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p><p><b>Carrier testing of minors.</b> Carrier testing of at-risk female relatives younger than age 18 years warrants consideration of specific issues, including the minor's experience (or lack of experience) with the disorder, the implications of the test results, the significance that she attributes to them, and the likelihood of her becoming a mother in the near future. The possible benefits of early testing and disclosure must be weighed against the potential harm of loss of autonomy [<a class="bk_pop" href="#x-scid.REF.fanos.2001.46">Fanos et al 2001</a>, <a class="bk_pop" href="#x-scid.REF.fanos.2001.57">Fanos &#x00026; Puck 2001</a>]. It is important to assess the minor's ability to understand options and consequences. A minor who can project into the future and has a stable set of values with which to weigh options is the best candidate to participate in determining whether or not to undergo X-SCID <a class="def" href="/books/n/gene/glossary/def-item/carrier-testing/">carrier testing</a>.</p><p>For more information, see the American Academy of Pediatrics and American College of Medical Genetics and Genomics <a href="http://pediatrics.aappublications.org/content/131/3/620.full.pdf" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">policy statement</a>: ethical and policy issues in genetic testing and screening of children.</p></div><div id="x-scid.Prenatal_Testing_and_Preimplantat"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p>Once the <i>IL2RG</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> are possible.</p><p><b>Percutaneous umbilical blood sampling (PUBS).</b> If the <i>IL2RG</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has not been identified, fetal blood sampling is considered in some centers. Fetal blood is analyzed for lymphocytopenia, low numbers of T cells, and poor T-cell blastogenic responses to mitogens, all of which can be definitively demonstrated in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> pregnancies by 17 weeks' gestation; however, caution is necessary as maternal blood contamination can yield false normal results. Involvement of experienced high-risk perinatologists, genetics experts, and immunologists is advised.</p><p>Note: Gestational age is expressed as menstrual weeks calculated either from the first day of the last normal menstrual period or by ultrasound measurements.</p><p>Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. While most centers would consider decisions regarding prenatal testing to be the choice of the parents, discussion of these issues is appropriate.</p></div></div><div id="x-scid.Resources"><h2 id="_x-scid_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>National Library of Medicine Genetics Home Reference</b></div><div><a href="http://ghr.nlm.nih.gov/condition=xlinkedseverecombinedimmunodeficiency" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">X-linked severe combined immunodeficiency</a></div></li><li class="half_rhythm"><div><b>Canadian Immunodeficiencies Patient Organization (CIPO)</b></div><div>362 Concession Road 12</div><div>RR #2</div><div>Hastings Ontario K0L 1Y0</div><div>Canada</div><div><b>Phone:</b> 877-262-2476 (toll-free)</div><div><b>Fax:</b> 866-942-7651 (toll-free)</div><div><b>Email:</b> info@cipo.ca</div><div><a href="http://cipo.ca" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.cipo.ca</a></div></li><li class="half_rhythm"><div><b>International Patient Organisation for Primary Immunodeficiencies (IPOPI)</b></div><div>Firside</div><div>Main Road</div><div>Downderry Cornwall PL11 3LE</div><div>United Kingdom</div><div><b>Phone:</b> +44 01503 250 668</div><div><b>Fax:</b> +44 01503 250 668</div><div><b>Email:</b> info@ipopi.org</div><div><a href="http://ipopi.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ipopi.org</a></div></li><li class="half_rhythm"><div><b>Jeffrey Modell Foundation/National Primary Immunodeficiency Resource Center</b></div><div>747 Third Avenue</div><div>New York NY 10017</div><div><b>Phone:</b> 866-463-6474 (toll-free); 212-819-0200</div><div><b>Fax:</b> 212-764-4180</div><div><b>Email:</b> info@jmfworld.org</div><div><a href="http://www.info4pi.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.info4pi.org</a></div></li><li class="half_rhythm"><div><b>National Human Genome Research Institute (NHGRI)</b></div><div><a href="http://www.genome.gov/13014325" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Learning About Severe Combined Immunodeficiency (SCID)</a></div></li><li class="half_rhythm"><div><b>NCBI Genes and Disease</b></div><div><a href="/books/NBK22254/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Severe combined immunodeficiency</a></div></li><li class="half_rhythm"><div><b>European Society for Immunodeficiencies (ESID) Registry</b></div><div>Dr. Gerhard Kindle</div><div>University Medical Center Freiburg Centre of Chronic Immunodeficiency</div><div>Engesserstr. 4</div><div>79106 Freiburg </div><div>Germany</div><div><b>Phone:</b> 49-761-270-34450</div><div><b>Email:</b> esid-registry@uniklinik-freiburg.de</div><div><a href="http://esid.org/Working-Parties/Registry" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ESID Registry</a></div></li><li class="half_rhythm"><div><b>Primary Immunodeficiency Diseases Registry at USIDNET</b></div><div>40 West Chesapeake Avenue</div><div>Suite 308</div><div>Towson MD 21204-4803</div><div><b>Phone:</b> 866-939-7568</div><div><b>Fax:</b> 410-321-0293</div><div><b>Email:</b> contact@usidnet.org</div><div><a href="http://usidnet.org/usidnet-registry/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Primary Immunodeficiency Registry at USIDNET</a></div></li><li class="half_rhythm"><div><b>RDCRN Patient Contact Registry: Primary Immune Deficiency Treatment Consortium</b></div><div><a href="https://www.rarediseasesnetwork.org/cms/pidtc" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Patient Contact Registry</a></div></li></ul></div><div id="x-scid.Molecular_Genetics"><h2 id="_x-scid_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="x-scid.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>X-Linked Severe Combined Immunodeficiency: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1410/table/x-scid.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__x-scid.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_x-scid.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_x-scid.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_x-scid.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_x-scid.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_x-scid.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_x-scid.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_x-scid.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/3561" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>IL2RG</i></a></td><td headers="hd_b_x-scid.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=3561" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Xq13<wbr style="display:inline-block"></wbr>​.1</a></td><td headers="hd_b_x-scid.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/P31785" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Cytokine receptor common subunit gamma</a></td><td headers="hd_b_x-scid.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.LOVD.nl/IL2RG" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">IL2RG @ LOVD</a><br /><a href="https://research.cchmc.org/LOVD2/home.php?select_db=IL2RG" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">CCHMC - Human Genetics Mutation Database (IL2RG)</a><br /><a href="https://www.ncbi.nlm.nih.gov/lovd/home.php?select_db=IL2RG" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">IL2RG @ LOVD at NCBI</a></td><td headers="hd_b_x-scid.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=IL2RG" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">IL2RG</a></td><td headers="hd_b_x-scid.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=IL2RG[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">IL2RG</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="x-scid.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="x-scid.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for X-Linked Severe Combined Immunodeficiency (<a href="/omim/300400,308380" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1410/table/x-scid.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__x-scid.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/300400" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">300400</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">SEVERE COMBINED IMMUNODEFICIENCY, X-LINKED; SCIDX1</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/308380" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">308380</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">INTERLEUKIN 2 RECEPTOR, GAMMA; IL2RG</td></tr></tbody></table></div></div><p><b>Gene structure.</b>
<i>IL2RG</i> spans 4.5 kb of <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> DNA. The coding sequence of 1,124 nucleotides is divided into eight exons (<a href="/nuccore/NM_000206.2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_000206.2</a>). <i>IL2RG</i> encodes the common gamma chain (&#x003b3;c), an essential component of the receptors for interleukins 2, 4, 7, 9, 15, and 21. For a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information, see <a href="/books/NBK1410/#x-scid.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Pathogenic variants.</b> More than 200 pathogenic variants spanning all eight exons of the <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> have been identified. They are primarily single-nucleotide changes or changes of a few nucleotides, small insertions, deletions, and splice defects. Mutational hot spots in <i>IL2RG</i> are reported at codons p.Arg224, p.Arg226, p.Arg285, and p.Arg289 [<a class="bk_pop" href="#x-scid.REF.puck.1996.507">Puck 1996</a>, <a class="bk_pop" href="#x-scid.REF.puck.1997.1835">Puck 1997</a>, <a class="bk_pop" href="#x-scid.REF.puck.1997b.1968">Puck et al 1997b</a>]. (For more information, see <a href="/books/NBK1410/#x-scid.molgen.TA">Table A</a>.)</p><div id="x-scid.T.il2rg_variants_discussed_in_thi" class="table"><h3><span class="label">Table 4. </span></h3><div class="caption"><p><i>IL2RG</i> Variants Discussed in This <i>GeneReview</i></p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1410/table/x-scid.T.il2rg_variants_discussed_in_thi/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__x-scid.T.il2rg_variants_discussed_in_thi_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_x-scid.T.il2rg_variants_discussed_in_thi_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change</th><th id="hd_h_x-scid.T.il2rg_variants_discussed_in_thi_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change</th><th id="hd_h_x-scid.T.il2rg_variants_discussed_in_thi_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th></tr></thead><tbody><tr><td headers="hd_h_x-scid.T.il2rg_variants_discussed_in_thi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.670C&#x0003e;T</td><td headers="hd_h_x-scid.T.il2rg_variants_discussed_in_thi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg224Trp</td><td headers="hd_h_x-scid.T.il2rg_variants_discussed_in_thi_1_1_1_3" rowspan="5" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/nuccore/115583676?report=genbank" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_000206<wbr style="display:inline-block"></wbr>​.2</a></td></tr><tr><td headers="hd_h_x-scid.T.il2rg_variants_discussed_in_thi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.676C&#x0003e;T</td><td headers="hd_h_x-scid.T.il2rg_variants_discussed_in_thi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg226Cys</td></tr><tr><td headers="hd_h_x-scid.T.il2rg_variants_discussed_in_thi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.677G&#x0003e;A</td><td headers="hd_h_x-scid.T.il2rg_variants_discussed_in_thi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg226His</td></tr><tr><td headers="hd_h_x-scid.T.il2rg_variants_discussed_in_thi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.854G&#x0003e;A</td><td headers="hd_h_x-scid.T.il2rg_variants_discussed_in_thi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg285Gln</td></tr><tr><td headers="hd_h_x-scid.T.il2rg_variants_discussed_in_thi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.865C&#x0003e;T</td><td headers="hd_h_x-scid.T.il2rg_variants_discussed_in_thi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg289Ter</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Note on variant classification: Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin">Note on nomenclature: <i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd></dl></div></div></div><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> The normal gene product is the common gamma chain, or gamma-c, which is a transmembrane protein in the cytokine receptor gene superfamily. It is a component of multiple cytokine receptors on the surface of lymphocytes and other hematopoietic cells, including the receptors for IL-2, -4, -7, -9, -15, and 21. Gamma-c has 389 amino acid residues (<a href="/protein/NP_000197.1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_000197.1</a>).</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> More than two thirds of pathogenic variants result in lack of protein expression; however, nonfunctional truncated gamma-c proteins or gamma-c proteins bearing amino acid substitutions, insertions, or deletions have been described.</p></div><div id="x-scid.References"><h2 id="_x-scid_References_">References</h2><div id="x-scid.Published_Guidelines__Consensus_S"><h3>Published Guidelines / Consensus Statements</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="x-scid.REF1">Committee on Bioethics, Committee on Genetics, and American College of Medical Genetics and Genomics Social, Ethical, Legal Issues Committee. Ethical and policy issues in genetic testing and screening of children. Available <a href="http://pediatrics.aappublications.org/content/131/3/620.full.pdf" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">online</a>. 2013. Accessed 2-21-19. [<a href="/pubmed/23428972" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23428972</span></a>]</div></li></ul></div><div id="x-scid.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="x-scid.REF.altman.1961">Altman PL. Blood leukocyte values: man. In: Dittmer DS, Altman PL, eds. <em>Blood and Other Body Fluids</em>. Washington, DC: Federation of American Societies for Experimental Biology; 1961:125-65.</div></li><li class="half_rhythm"><div class="bk_ref" id="x-scid.REF.baker.2009.522">Baker MW, Grossman WJ, Laessig RH, Hoffman GL, Brokopp CD, Kurtycz DF, Cogley MF, Litsheim TJ, Katcher ML, Routes JM. Development of a routine newborn screening protocol for severe combined immunodeficiency. <span><span class="ref-journal">J Allergy Clin Immunol. </span>2009;<span class="ref-vol">124</span>:522–7.</span> [<a href="/pubmed/19482345" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19482345</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="x-scid.REF.buckley.1997.378">Buckley RH, Schiff RI, Schiff SE, Markert ML, Williams LW, Harville TO, Roberts JL, Puck JM. Human severe combined immunodeficiency: genetic, phenotypic, and functional diversity in one hundred eight infants. <span><span class="ref-journal">J Pediatr. </span>1997;<span class="ref-vol">130</span>:378–87.</span> [<a href="/pubmed/9063412" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9063412</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="x-scid.REF.buckley.1999.508">Buckley RH, Schiff SE, Schiff RI, Markert L, Williams LW, Roberts JL, Myers LA, Ward FE. Hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency. <span><span class="ref-journal">N Engl J Med. </span>1999;<span class="ref-vol">340</span>:508–16.</span> [<a href="/pubmed/10021471" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10021471</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="x-scid.REF.buckley.2012.597">Buckley RH. The long quest for neonatal screening for severe combined immunodeficiency. <span><span class="ref-journal">J Allergy Clin Immunol. </span>2012;<span class="ref-vol">129</span>:597–604.</span> [<a href="/pmc/articles/PMC3294102/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3294102</span></a>] [<a href="/pubmed/22277203" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22277203</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="x-scid.REF.chan.2005.391">Chan K, Puck JM. Development of population-based newborn screening for severe combined immunodeficiency. <span><span class="ref-journal">J Allergy Clin Immunol. </span>2005;<span class="ref-vol">115</span>:391–8.</span> [<a href="/pubmed/15696101" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15696101</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="x-scid.REF.chase.2010.521">Chase NM, Verbsky JW, Routes JM. Newborn screening for T-cell deficiency. <span><span class="ref-journal">Curr Opin Allergy Clin Immunol. </span>2010;<span class="ref-vol">10</span>:521–5.</span> [<a href="/pubmed/20864885" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20864885</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="x-scid.REF.clark.1995.427">Clark PA, Lester T, Genet S, Jones AM, Hendriks R, Levinsky RJ, Kinnon C. Screening for mutations causing X-linked severe combined immunodeficiency in the IL-2R gamma chain gene by single-strand conformation polymorphism analysis. <span><span class="ref-journal">Hum Genet. </span>1995;<span class="ref-vol">96</span>:427–32.</span> [<a href="/pubmed/7557965" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7557965</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="x-scid.REF.conley.1990.1548">Conley ME, Buckley RH, Hong R, Guerra-Hanson C, Roifman CM, Brochstein JA, Pahwa S, Puck JM. X-linked severe combined immunodeficiency. Diagnosis in males with sporadic severe combined immunodeficiency and clarification of clinical findings. <span><span class="ref-journal">J Clin Invest. </span>1990;<span class="ref-vol">85</span>:1548–54.</span> [<a href="/pmc/articles/PMC296604/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC296604</span></a>] [<a href="/pubmed/2332505" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2332505</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="x-scid.REF.conley.1996">Conley ME, Stiehm ER. Immunodeficiency disorders. In: Stiehm ER, ed. <em>Immunologic Disorders in Infants and Children</em>. 4 ed. Philadelphia, PA: WB Saunders; 1996:216-7.</div></li><li class="half_rhythm"><div class="bk_ref" id="x-scid.REF.deichmann.2011.2031">Deichmann A, Brugman MH, Bartholomae CC, Schwarzwaelder K, Verstegen MM, Howe SJ, Arens A, Ott MG, Hoelzer D, Seger R, Grez M, Hacein-Bey-Abina S, Cavazzana-Calvo M, Fischer A, Paruzynski A, Gabriel R, Glimm H, Abel U, Cattoglio C, Mavilio F, Cassani B, Aiuti A, Dunbar CE, Baum C, Gaspar HB, Thrasher AJ, von Kalle C, Schmidt M, Wagemaker G. Insertion sites in engrafted cells cluster within a limited repertoire of genomic areas after gammaretroviral vector gene therapy. <span><span class="ref-journal">Mol Ther. </span>2011;<span class="ref-vol">19</span>:2031–9.</span> [<a href="/pmc/articles/PMC3222531/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3222531</span></a>] [<a href="/pubmed/21862999" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21862999</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="x-scid.REF.denianke.2001.227">Denianke KS, Frieden IJ, Cowan MJ, Williams ML, McCalmont TH. Cutaneous manifestations of maternal engraftment in patients with severe combined immunodeficiency: a clinicopathologic study. <span><span class="ref-journal">Bone Marrow Transplant. </span>2001;<span class="ref-vol">28</span>:227–33.</span> [<a href="/pubmed/11535989" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11535989</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="x-scid.REF.disanto.1994.9466">DiSanto JP, Rieux-Laucat F, Dautry-Varsat A, Fischer A, de Saint Basile G. Defective human interleukin 2 receptor gamma chain in an atypical X chromosome-linked severe combined immunodeficiency with peripheral T cells. <span><span class="ref-journal">Proc Natl Acad Sci U S A. </span>1994;<span class="ref-vol">91</span>:9466–70.</span> [<a href="/pmc/articles/PMC44833/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC44833</span></a>] [<a href="/pubmed/7937790" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7937790</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="x-scid.REF.fanos.2001.46">Fanos JH, Davis J, Puck JM. Sib understanding of genetics and attitudes toward carrier testing for X-linked severe combined immunodeficiency. <span><span class="ref-journal">Am J Med Genet. </span>2001;<span class="ref-vol">98</span>:46–56.</span> [<a href="/pubmed/11426455" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11426455</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="x-scid.REF.fanos.2001.57">Fanos JH, Puck JM. Family pictures: growing up with a brother with X-linked severe combined immunodeficiency. <span><span class="ref-journal">Am J Med Genet. </span>2001;<span class="ref-vol">98</span>:57–63.</span> [<a href="/pubmed/11426456" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11426456</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="x-scid.REF.fischer.2011.1356">Fischer A, Hacein-Bey-Abina S, Cavazzana-Calvo M. Gene therapy for primary adaptive immune deficiencies. <span><span class="ref-journal">J Allergy Clin Immunol. </span>2011;<span class="ref-vol">127</span>:1356–9.</span> [<a href="/pubmed/21624615" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21624615</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="x-scid.REF.fuchs.2014.3129">Fuchs S, Rensing-Ehl A, Erlacher M, Vraetz T, Hartjes L, Janda A, Rizzi M, Lorenz MR, Gilmour K, de Saint-Basile G, Roifman CM, Cheuk S, Gennery A, Thrasher AJ, Fuchs I, Schwarz K, Speckmann C, Ehl S. Patients with T<sup>+</sup>/low NK<sup>+</sup> IL-2 receptor &#x003b3; chain deficiency have differentially-impaired cytokine signaling resulting in severe combined immunodeficiency. <span><span class="ref-journal">Eur J Immunol. </span>2014;<span class="ref-vol">44</span>:3129–40.</span> [<a href="/pubmed/25042067" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25042067</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="x-scid.REF.haceinbey.1996.3108">Hacein-Bey H, Cavazzana-Calvo M, Le Deist F, Dautry-Varsat A, Hivroz C, Rivi&#x000e8;re I, Danos O, Heard JM, Sugamura K, Fischer A, De Saint Basile G. gamma-c gene transfer into SCID X1 patients' B-cell lines restores normal high-affinity interleukin-2 receptor expression and function. <span><span class="ref-journal">Blood. </span>1996;<span class="ref-vol">87</span>:3108–16.</span> [<a href="/pubmed/8605324" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8605324</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="x-scid.REF.haceinbeyabina.2010.355">Hacein-Bey-Abina S, Hauer J, Lim A, Picard C, Wang GP, Berry CC, Martinache C, Rieux-Laucat F, Latour S, Belohradsky BH, Leiva L, Sorensen R, Debr&#x000e9; M, Casanova JL, Blanche S, Durandy A, Bushman FD, Fischer A, Cavazzana-Calvo M. <span><span class="ref-journal">N Engl J Med. </span>2010;<span class="ref-vol">363</span>:355–64.</span> [<a href="/pmc/articles/PMC2957288/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2957288</span></a>] [<a href="/pubmed/20660403" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20660403</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="x-scid.REF.haceinbeyabina.2014.1407">Hacein-Bey-Abina S, Pai SY, Gaspar HB, Armant M, Berry CC, Blanche S, Bleesing J, Blondeau J, de Boer H, Buckland KF, Caccavelli L, Cros G, De Oliveira S, Fernandez KS, Guo D, Harris CE, Hopkins G, Lehmann LE, Lim A, London WB, van der Loo JC, Malani N, Male F, Malik P, Marinovic MA, McNicol AM, Moshous D, Neven B, Oleastro M, Picard C, Ritz J, Rivat C, Schambach A, Shaw KL, Sherman EA, Silberstein LE, Six E, Touzot F, Tsytsykova A, Xu-Bayford J, Baum C, Bushman FD, Fischer A, Kohn DB, Filipovich AH, Notarangelo LD, Cavazzana M, Williams DA, Thrasher AJ. A modified &#x003b3;-retrovirus vector for X-linked severe combined immunodeficiency. <span><span class="ref-journal">N Engl J Med. </span>2014;<span class="ref-vol">371</span>:1407–17.</span> [<a href="/pmc/articles/PMC4274995/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4274995</span></a>] [<a href="/pubmed/25295500" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25295500</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="x-scid.REF.howe.2008.3143">Howe SJ, Mansour MR, Schwarzwaelder K, Bartholomae C, Hubank M, Kempski H, Brugman MH, Pike-Overzet K, Chatters SJ, de Ridder D, Gilmour KC, Adams S, Thornhill SI, Parsley KL, Staal FJ, Gale RE, Linch DC, Bayford J, Brown L, Quaye M, Kinnon C, Ancliff P, Webb DK, Schmidt M, von Kalle C, Gaspar HB, Thrasher AJ. <span><span class="ref-journal">J Clin Invest. </span>2008;<span class="ref-vol">118</span>:3143–50.</span> [<a href="/pmc/articles/PMC2496964/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2496964</span></a>] [<a href="/pubmed/18688286" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18688286</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="x-scid.REF.kane.2001.f110">Kane L, Gennery AR, Crooks BN, Flood TJ, Abinun M, Cant AJ. Neonatal bone marrow transplantation for severe combined immunodeficiency. <span><span class="ref-journal">Arch Dis Child Fetal Neonatal Ed. </span>2001;<span class="ref-vol">85</span>:F110–3.</span> [<a href="/pmc/articles/PMC1721317/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1721317</span></a>] [<a href="/pubmed/11517204" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11517204</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="x-scid.REF.kwan.2014.729">Kwan A, Abraham RS, Currier R, Brower A, Andruszewski K, Abbott JK, Baker M, Ballow M, Bartoshesky LE, Bonilla FA, Brokopp C, Brooks E, Caggana M, Celestin J, Church JA, Comeau AM, Connelly JA, Cowan MJ, Cunningham-Rundles C, Dasu T, Dave N, De La Morena MT, Duffner U, Fong CT, Forbes L, Freedenberg D, Gelfand EW, Hale JE, Hanson IC, Hay BN, Hu D, Infante A, Johnson D, Kapoor N, Kay DM, Kohn DB, Lee R, Lehman H, Lin Z, Lorey F, Abdel-Mageed A, Manning A, McGhee S, Moore TB, Naides SJ, Notarangelo LD, Orange JS, Pai SY, Porteus M, Rodriguez R, Romberg N, Routes J, Ruehle M, Rubenstein A, Saavedra-Matiz CA, Scott G, Scott PM, Secord E, Seroogy C, Shearer WT, Siegel S, Silvers SK, Stiehm ER, Sugerman RW, Sullivan JL, Tanksley S, Tierce ML 4th, Verbsky J, Vogel B, Walker R, Walkovich K, Walter JE, Wasserman RL, Watson MS, Weinberg GA, Weiner LB, Wood H, Yates AB, Puck JM, Bonagura VR. Newborn screening for severe combined immunodeficiency in 11 screening programs in the United States. <span><span class="ref-journal">JAMA. </span>2014;<span class="ref-vol">312</span>:729–38.</span> [<a href="/pmc/articles/PMC4492158/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4492158</span></a>] [<a href="/pubmed/25138334" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25138334</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="x-scid.REF.lee.2011.281">Lee PP, Chan KW, Chen TX, Jiang LP, Wang XC, Zeng HS, Chen XY, Liew WK, Chen J, Chu KM, Chan LL, Shek L, Lee AC, Yu HH, Li Q, Xu CG, Sultan-Ugdoracion G, Latiff ZA, Latiff AH, Jirapongsananuruk O, Ho MH, Lee TL, Yang XQ, Lau YL. Molecular diagnosis of severe combined immunodeficiency--identification of IL2RG, JAK3, IL7R, DCLRE1C, RAG1, and RAG2 mutations in a cohort of Chinese and Southeast Asian children. <span><span class="ref-journal">J Clin Immunol. </span>2011;<span class="ref-vol">31</span>:281–96.</span> [<a href="/pubmed/21184155" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21184155</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="x-scid.REF.morelon.1996.1708">Morelon E, Dautry-Varsat A, Le Deist F, Hacein-Bay S, Fischer A, de Saint Basile G. T-lymphocyte differentiation and proliferation in the absence of the cytoplasmic tail of the common cytokine receptor gamma c chain in a severe combined immune deficiency X1 patient. <span><span class="ref-journal">Blood. </span>1996;<span class="ref-vol">88</span>:1708–17.</span> [<a href="/pubmed/8781427" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8781427</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="x-scid.REF.myers.2002.872">Myers LA, Patel DD, Puck JM, Buckley RH. Hematopoietic stem cell transplantation for severe combined immunodeficiency in the neonatal period leads to superior thymic output and improved survival. <span><span class="ref-journal">Blood. </span>2002;<span class="ref-vol">99</span>:872–8.</span> [<a href="/pubmed/11806989" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11806989</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="x-scid.REF.niemela.2000.33">Niemela JE, Puck JM, Fischer RE, Fleisher TA, Hsu AP. Efficient detection of thirty-seven new IL2RG mutations in human X-linked severe combined immunodeficiency. <span><span class="ref-journal">Clin Immunol. </span>2000;<span class="ref-vol">95</span>:33–8.</span> [<a href="/pubmed/10794430" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10794430</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="x-scid.REF.noguchi.1993.147">Noguchi M, Yi H, Rosenblatt HM, Filipovich AH, Adelstein S, Modi WS, McBride OW, Leonard WJ. Interleukin-2 receptor gamma chain mutation results in X-linked severe combined immunodeficiency in humans. <span><span class="ref-journal">Cell. </span>1993;<span class="ref-vol">73</span>:147–57.</span> [<a href="/pubmed/8462096" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8462096</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="x-scid.REF.omarcaigh.1997.29">O'Marcaigh AS, Puck JM, Pepper AE, De Santes K, Cowan MJ. Maternal mosaicism for a novel interleukin-2 receptor gamma-chain mutation causing X-linked severe combined immunodeficiency in a Navajo kindred. <span><span class="ref-journal">J Clin Immunol. </span>1997;<span class="ref-vol">17</span>:29–33.</span> [<a href="/pubmed/9049783" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9049783</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="x-scid.REF.oreilly.1989.273">O'Reilly RJ, Keever CA, Small TN, Brochstein J. The use of HLA-non-identical T-cell-depleted marrow transplants for correction of severe combined immunodeficiency disease. <span><span class="ref-journal">Immunodefic Rev. </span>1989;<span class="ref-vol">1</span>:273–309.</span> [<a href="/pubmed/2698644" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2698644</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="x-scid.REF.okuno.2015.610">Okuno Y, Hoshino A, Muramatsu H, Kawashima N, Wang X, Yoshida K, Wada T, Gunji M, Toma T, Kato T, Shiraishi Y, Iwata A, Hori T, Kitoh T, Chiba K, Tanaka H, Sanada M, Takahashi Y, Nonoyama S, Ito M, Miyano S, Ogawa S, Kojima S, Kanegane H. Late-onset combined immunodeficiency with a novel IL2RG mutation and probable revertant somatic mosaicism. <span><span class="ref-journal">J Clin Immunol. </span>2015;<span class="ref-vol">35</span>:610–4.</span> [<a href="/pubmed/26407811" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26407811</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="x-scid.REF.pai.2014.434">Pai SY, Logan BR, Griffith LM, Buckley RH, Parrott RE, Dvorak CC, Kapoor N, Hanson IC, Filipovich AH, Jyonouchi S, Sullivan KE, Small TN, Burroughs L, Skoda-Smith S, Haight AE, Grizzle A, Pulsipher MA, Chan KW, Fuleihan RL, Haddad E, Loechelt B, Aquino VM, Gillio A, Davis J, Knutsen A, Smith AR, Moore TB, Schroeder ML, Goldman FD, Connelly JA, Porteus MH, Xiang Q, Shearer WT, Fleisher TA, Kohn DB, Puck JM, Notarangelo LD, Cowan MJ, O'Reilly RJ. Transplantation outcomes for severe combined immunodeficiency, 2000-2009. <span><span class="ref-journal">N Engl J Med. </span>2014;<span class="ref-vol">371</span>:434–46.</span> [<a href="/pmc/articles/PMC4183064/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4183064</span></a>] [<a href="/pubmed/25075835" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25075835</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="x-scid.REF.puck.1996.507">Puck JM. IL2RGbase: a database of gamma c-chain defects causing human X-SCID. <span><span class="ref-journal">Immunol Today. </span>1996;<span class="ref-vol">17</span>:507–11.</span> [<a href="/pubmed/8961626" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8961626</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="x-scid.REF.puck.2012.607">Puck JM. Laboratory technology for population-based screening for severe combined immunodeficiency in neonates: the winner is T-cell receptor excision circles. <span><span class="ref-journal">J Allergy Clin Immunol. </span>2012;<span class="ref-vol">129</span>:607–16.</span> [<a href="/pmc/articles/PMC3294074/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3294074</span></a>] [<a href="/pubmed/22285280" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22285280</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="x-scid.REF.puck.1997.1835">Puck JM. Primary immunodeficiency diseases. <span><span class="ref-journal">JAMA. </span>1997;<span class="ref-vol">278</span>:1835–41.</span> [<a href="/pubmed/9396644" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9396644</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="x-scid.REF.puck.1999">Puck JM. X-linked severe combined immunodeficiency. In: Ochs H, Smith CIE, Puck JM, eds. <em>Primary Immunodeficiency Diseases, a Molecular and Genetic Approach</em>. New York, NY: Oxford University Press; 1999:99-110.</div></li><li class="half_rhythm"><div class="bk_ref" id="x-scid.REF.puck.1993.1099">Puck JM, Desch&#x000ea;nes SM, Porter JC, Dutra AS, Brown CJ, Willard HF, Henthorn PS. The interleukin-2 receptor gamma chain maps to Xq13.1 and is mutated in X-linked severe combined immunodeficiency, SCIDX1. <span><span class="ref-journal">Hum Mol Genet. </span>1993;<span class="ref-vol">2</span>:1099–104.</span> [<a href="/pubmed/8401490" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8401490</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="x-scid.REF.puck.1997a.628">Puck JM, Middelton L, Pepper AE. Carrier and prenatal diagnosis of X-linked severe combined immunodeficiency: mutation detection methods and utilization. <span><span class="ref-journal">Hum Genet. </span>1997a;<span class="ref-vol">99</span>:628–33.</span> [<a href="/pubmed/9150730" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9150730</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="x-scid.REF.puck.1997b.1968">Puck JM, Pepper AE, Henthorn PS, Candotti F, Isakov J, Whitwam T, Conley ME, Fischer RE, Rosenblatt HM, Small TN, Buckley RH. Mutation analysis of IL2RG in human X-linked severe combined immunodeficiency. <span><span class="ref-journal">Blood. </span>1997b;<span class="ref-vol">89</span>:1968–77.</span> [<a href="/pubmed/9058718" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9058718</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="x-scid.REF.schmalstieg.1995.1169">Schmalstieg FC, Leonard WJ, Noguchi M, Berg M, Rudloff HE, Denney RM, Dave SK, Brooks EG, Goldman AS. Missense mutation in exon 7 of the common gamma chain gene causes a moderate form of X-linked combined immunodeficiency. <span><span class="ref-journal">J Clin Invest. </span>1995;<span class="ref-vol">95</span>:1169–73.</span> [<a href="/pmc/articles/PMC441454/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC441454</span></a>] [<a href="/pubmed/7883965" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7883965</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="x-scid.REF.shearer.2003.973">Shearer WT, Rosenblatt HM, Gelman RS, Oyomopito R, Plaeger S, Stiehm ER, Wara DW, Douglas SD, Luzuriaga K, McFarland EJ, Yogev R, Rathore MH, Levy W, Graham BL, Spector SA., Pediatric AIDS Clinical Trials Group.  Lymphocyte subsets in healthy children from birth through 18 years of age: the Pediatric AIDS Clinical Trials Group P1009 study. <span><span class="ref-journal">J Allergy Clin Immunol. </span>2003;<span class="ref-vol">112</span>:973–80.</span> [<a href="/pubmed/14610491" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14610491</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="x-scid.REF.stephan.1993.564">Stephan JL, Vlekova V, Le Deist F, Blanche S, Donadieu J, De Saint-Basile G, Durandy A, Griscelli C, Fischer A. Severe combined immunodeficiency: a retrospective single-center study of clinical presentation and outcome in 117 patients. <span><span class="ref-journal">J Pediatr. </span>1993;<span class="ref-vol">123</span>:564–72.</span> [<a href="/pubmed/8410508" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8410508</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="x-scid.REF.stephan.1996.1563">Stephan V, Wahn V, Le Deist F, Dirksen U, Broker B, M&#x000fc;ller-Fleckenstein I, Horneff G, Schroten H, Fischer A, de Saint Basile G. Atypical X-linked severe combined immunodeficiency due to possible spontaneous reversion of the genetic defect in T cells. <span><span class="ref-journal">N Engl J Med. </span>1996;<span class="ref-vol">335</span>:1563–7.</span> [<a href="/pubmed/8900089" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8900089</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="x-scid.REF.zhang.2013.42">Zhang C, Zhang ZY, Wu JF, Tang XM, Yang XQ, Jiang LP, Zhao XD. Clinical characteristics and mutation analysis of X-linked severe combined immunodeficiency in China. <span><span class="ref-journal">World J Pediatr. </span>2013;<span class="ref-vol">9</span>:42–7.</span> [<a href="/pubmed/22105576" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22105576</span></a>]</div></li></ul></div></div><div id="x-scid.Chapter_Notes"><h2 id="_x-scid_Chapter_Notes_">Chapter Notes</h2><div id="x-scid.Author_History"><h3>Author History</h3><p>Eric J Allenspach, MD, PhD (2013-present)<br />Joie Davis, APRN, BC, APNG; National Institutes of Health (2003-2013)<br />Jennifer M Puck, MD; University of California, San Francisco (2003-2013)<br />David J Rawlings, MD (2013-present)<br />Andrew Scharenberg, MD (2013-present)</p></div><div id="x-scid.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>14 April 2016 (sw) Comprehensive update posted live</div></li><li class="half_rhythm"><div>30 July 2015 (ea/ams) Revision: <i>STAT5a</i> removed from Differential Diagnosis</div></li><li class="half_rhythm"><div>24 January 2013 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>12 December 2005 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>26 August 2003 (me) Review posted live</div></li><li class="half_rhythm"><div>23 April 2003 (jd) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK1410</span><span class="label">PMID: <a href="/pubmed/20301584" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">20301584</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/epp-xl/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/sider-anemia/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK1410&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK1410/?report=reader">PubReader</a></li><li><a href="/books/NBK1410/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK1410" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK1410" style="display:none" title="Cite this Page"><div class="bk_tt">Allenspach E, Rawlings DJ, Scharenberg AM. X-Linked Severe Combined Immunodeficiency. 2003 Aug 26 [Updated 2016 Apr 14]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK1410/pdf/Bookshelf_NBK1410.pdf">PDF version of this page</a> (243K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#x-scid.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#x-scid.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#x-scid.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#x-scid.Genetically_Related_Allelic_Disor" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#x-scid.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#x-scid.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#x-scid.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#x-scid.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#x-scid.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#x-scid.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#x-scid.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=3561[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">IL2RG</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=1459174" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=1459174" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=1459174" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=1459174" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301656" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Adenosine Deaminase Deficiency</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Adenosine Deaminase Deficiency<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Hershfield M. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301626" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> X-Linked Agammaglobulinemia</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> X-Linked Agammaglobulinemia<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Smith CIE, Berglöf A. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301576" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> X-Linked Hyper IgM Syndrome</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> X-Linked Hyper IgM Syndrome<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Johnson J, Filipovich AH, Zhang K. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301575" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Fanconi Anemia</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Fanconi Anemia<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Mehta PA, Tolar J. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301357" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">WAS</i>-Related Disorders</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">WAS</i>-Related Disorders<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Chandra S, Bronicki L, Nagaraj CB, Zhang K. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=20301584" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=20301584" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e040c5139a66ee2ba476a23">X-Linked Severe Combined Immunodeficiency - GeneReviews®</a><div class="ralinkpop offscreen_noflow">X-Linked Severe Combined Immunodeficiency - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T20:26:41-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal101&amp;ncbi_phid=CE88DFEDE040C1410000000000160004&amp;ncbi_session=CE88DFEDE040C501_0022SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK1410%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK1410&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK1410/&amp;ncbi_pagename=X-Linked Severe Combined Immunodeficiency - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE88DFEDE040C501_0022SID /projects/books/PBooks@5.22 portal101 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>